<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004329.pub2" GROUP_ID="ENT" ID="542003011411571879" MERGED_FROM="" MODIFIED="2015-04-27 11:17:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-04-27 11:17:17 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0091" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-04-27 11:17:17 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma</TITLE>
<CONTACT>
<PERSON ID="B4F857FD82E26AA201609AF920BD3C48" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bertrand</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Baujat</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bertrand.baujat@tnn.aphp.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service ORL-CCF</DEPARTMENT>
<ORGANISATION>Hôpital Tenon</ORGANISATION>
<ADDRESS_1>4 rue de la Chine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP>75020</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 146262297</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-04-27 11:12:09 +0100" MODIFIED_BY="Jenny Bellorini">
<PERSON ID="B4F857FD82E26AA201609AF920BD3C48" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bertrand</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Baujat</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bertrand.baujat@tnn.aphp.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service ORL-CCF</DEPARTMENT>
<ORGANISATION>Hôpital Tenon</ORGANISATION>
<ADDRESS_1>4 rue de la Chine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP>75020</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 146262297</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F85B7882E26AA201609AF99E7A76D1" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Hélène</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Audry</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>haudry3@yahoo.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Biostatistique et Epidémiologie</DEPARTMENT>
<ORGANISATION>Institut Gustave-Roussy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>94805 Villejuif Cedex</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8776" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jean</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bourhis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bourhis@igr.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Département de Radiothérapie</DEPARTMENT>
<ORGANISATION>Institut Gustave Roussy</ORGANISATION>
<ADDRESS_1>39 rue Camille Desmoulins</ADDRESS_1>
<ADDRESS_2/>
<CITY>Villejuif Cedex</CITY>
<ZIP>94805</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F8590782E26AA201609AF91E0E89A6" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS>TC</MIDDLE_INITIALS>
<LAST_NAME>Chan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>anthony@clo.cuhk.edu.hk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Oncology</DEPARTMENT>
<ORGANISATION>Prince of Wales Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Shatin</CITY>
<ZIP/>
<REGION>NT</REGION>
<COUNTRY CODE="HK">Hong Kong</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D5521D9082E26AA20047FC71761369E1" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Haluk</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Onat</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>honat@superonline.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Oncology</DEPARTMENT>
<ORGANISATION>Istanbul University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Istanbul</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="TR">Turkey</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F859D282E26AA201609AF9FA2877C6" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Daniel</FIRST_NAME>
<MIDDLE_INITIALS>TT</MIDDLE_INITIALS>
<LAST_NAME>Chua</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dttchua@hkucc.hku.hk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Oncology</DEPARTMENT>
<ORGANISATION>Queen Mary Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Hong Kong Island</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="HK">Hong Kong</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F85A9D82E26AA201609AF9DAD590F0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Dora</FIRST_NAME>
<MIDDLE_INITIALS>LW</MIDDLE_INITIALS>
<LAST_NAME>Kwong</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dlwkwong@hkucc.hku.hk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Oncology</DEPARTMENT>
<ORGANISATION>Queen Mary Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Hong Kong Island</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="HK">Hong Kong</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F85E5682E26AA201609AF9CAAA5F6F" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Muhyi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Al-Sarraf</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mealsarraf@aol.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>Wayne State University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Detroit</CITY>
<ZIP/>
<REGION>Michigan</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F85D1D82E26AA201609AF9F187C722" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kwan-Hwa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>khchi@vghtpe.gov.tw</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Taiwan Co-operative Oncology Group</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Taipei</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="TW">Taiwan</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F85F2182E26AA201609AF9686D646E" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Masato</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hareyama</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>hareyama@sapmed.ac.jp</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Radiology</DEPARTMENT>
<ORGANISATION>Sapporo Medical University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sapporo</CITY>
<ZIP>060-8556</ZIP>
<REGION/>
<COUNTRY CODE="JP">Japan</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B4F85FFC82E26AA201609AF91CAC09DA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Singh</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Leung</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sfleung@clo.cuhk.edu.hk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Oncology</DEPARTMENT>
<ORGANISATION>Prince of Wales Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Shatin</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="HK">Hong Kong</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="95D64ED982E26AA201C330AAA46AB211" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kullathorn</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thephamongkhol</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kullathorn@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Div of Radiation Oncology Department of Radiology</DEPARTMENT>
<ORGANISATION>Faculty of Medicine Siriraj Hospital Mahidol University</ORGANISATION>
<ADDRESS_1>2 Prannok Road Bangkoknoi</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bangkok</CITY>
<ZIP>10700</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+662 419 7082</PHONE_1>
<PHONE_2/>
<FAX_1>+662 419 77084</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D425812D82E26AA20112CE69F012F222" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jean Pierre</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pignon</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION/>
<EMAIL_1>jean-pierre.pignon@gustaveroussy.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Plateforme LNCC de Méta-analyse en Oncologie et Service de Biostatistique et d&#8217;Epidémiologie</DEPARTMENT>
<ORGANISATION>Gustave Roussy Cancer Campus</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Villejuif</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+ 33 1 4211 4565</PHONE_1>
<PHONE_2/>
<FAX_1>+ 33 1 4211 5258</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<GROUP ID="6D6274D982E26AA20075541C773A83EC">
<GROUP_NAME>MAC-NPC Collaborative Group</GROUP_NAME>
<CONTACT_PERSON>Bertrand Baujat</CONTACT_PERSON>
<EMAIL_1>b.baujat@hopital-foch.org</EMAIL_1>
<URL/>
<ADDRESS>
<DEPARTMENT>Head and Neck Surgery</DEPARTMENT>
<ORGANISATION>Hôpital Foch</ORGANISATION>
<ADDRESS_1>40 rue Worth</ADDRESS_1>
<ADDRESS_2/>
<CITY>Suresnes</CITY>
<ZIP>92150</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 146262297</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</GROUP>
</CREATORS>
<DATES MODIFIED="2008-11-05 15:39:26 +0000" MODIFIED_BY="Jenny Bellorini">
<UP_TO_DATE>
<DATE DAY="23" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="8" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="8" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2015-04-27 11:17:17 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-04-27 11:17:17 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>Author reply to feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-04-27 11:16:49 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-04-27 11:16:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Statement about unrestricted pharmaceutical company grants moved from 'Acknowledgements' to <LINK TAG="CONFLICT_OF_INTEREST" TYPE="SECTION">Declarations of interest</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-04-27 11:16:49 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>
<LINK TAG="FEEDBACK" TYPE="SECTION">Feedback</LINK> received.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-03-24 09:49:57 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Published note added regarding the future updating of this review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-27 16:17:17 +0100" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Institut Gustave-Roussy</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Aventis</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Sanofi-Synthelabo</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Schering-Plough</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-03-24 09:51:45 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma</TITLE>
<SUMMARY_BODY>
<P>Eight trials (1753 patients) met the criteria for inclusion in this review. The addition of chemotherapy to standard radiotherapy provides a small but significant benefit in patients with nasopharyngeal cancer, especially when chemotherapy is administered at the same time as radiotherapy. The role of chemotherapy given before or after the radiotherapy is more questionable.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>A previous meta-analysis investigated the role of chemotherapy in head and neck locally advanced carcinoma. This work had not been performed on nasopharyngeal carcinoma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The aim of the project was to study the effect of adding chemotherapy to radiotherapy on overall survival (OS) and event-free survival (EFS) in patients with nasopharyngeal carcinoma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched MEDLINE (1966 to October 2003), EMBASE (1980 to October 2003) and the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 3, 2003) and trial registers. Handsearches of meeting abstracts, references in review articles and of the Chinese medical literature were carried out. Experts and pharmaceutical companies were asked to identify trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing chemotherapy plus radiotherapy to radiotherapy alone in locally advanced nasopharyngeal carcinoma were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The meta-analysis was based on updated individual patient data. The log rank test, stratified by trial, was used for comparisons and the hazard ratios (HR) of death and failure (loco-regional/distant failure or death) were calculated. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eight trials with 1753 patients were included. One trial with a 2 x 2 design was counted twice in the analysis. The analysis was performed including 11 comparisons based on 1975 patients. The median follow up was six years. The pooled hazard ratio of death was 0.82 (95% confidence interval (CI) 0.71 to 0.95; P = 0.006) corresponding to an absolute survival benefit of 6% at five years from chemotherapy (from 56% to 62%). The pooled hazard ratio of tumour failure or death was 0.76 (95% CI 0.67 to 0.86; P &lt; 0.00001) corresponding to an absolute event-free survival benefit of 10% at five years from chemotherapy (from 42% to 52%). A significant interaction was observed between chemotherapy timings and overall survival (P = 0.005), explaining the heterogeneity observed in the treatment effect (P = 0.03) with the highest benefit from concomitant chemotherapy.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Chemotherapy led to a small but significant benefit for overall survival and event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with radiotherapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<BACKGROUND>
<P>Nasopharyngeal carcinoma (NPC) is pathologically, epidemiologically and clinically distinct from other head and neck cancers (<LINK REF="REF-Ali-2000" TYPE="REFERENCE">Ali 2000</LINK>; <LINK REF="REF-Vokes-1997" TYPE="REFERENCE">Vokes 1997</LINK>). Nasopharyngeal carcinoma is rare in the USA and Western Europe and in these areas, the frequency of squamous cell carcinoma (World Health Organization (WHO) type 1) is about 25%, which is markedly higher than in endemic areas. Endemic areas include Southern China, Southeast Asia, Middle East, North Africa, Alaska and Greenland. In these areas there is a strong correlation between Epstein-Barr virus latency and nasopharyngeal carcinoma. Most patients have a poorly or undifferentiated carcinoma (WHO type 2 or 3)and present with locally advanced stage disease. Nodal involvement and bilateral nodal disease are more frequently observed with nasopharyngeal carcinoma than with other head and neck cancers. </P>
<P>Nasopharyngeal carcinoma is commonly treated with radiation therapy and chemotherapy (<LINK REF="REF-Ali-2000" TYPE="REFERENCE">Ali 2000</LINK>). Radiotherapy at a dose of 65 to 75 Gray (Gy) over six to seven weeks is the standard treatment. Overall survival (OS) at five years ranges from 32% to 52% in large series of patients with locally advanced disease treated with radiotherapy alone (<LINK REF="REF-Ali-2000" TYPE="REFERENCE">Ali 2000</LINK>). </P>
<P>Chemotherapy has been proposed for locally advanced nasopharyngeal carcinoma to improve survival (<LINK REF="REF-Ali-2000" TYPE="REFERENCE">Ali 2000</LINK>; <LINK REF="REF-Vokes-1997" TYPE="REFERENCE">Vokes 1997</LINK>). In spite of 11 randomised trials comparing radiotherapy to radiotherapy plus chemotherapy in the English language literature, the magnitude of the effect of chemotherapy on survival is not well-established. Overall survival was a main endpoint in all of these trials excepted one, but only four trials showed a beneficial effect on event-free survival, and two of them showed a beneficial effect on overall survival. Underpowered trials could account for the inconstancy of the benefit for survival, which was the case in the previously published Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) (<LINK REF="REF-Pignon-2000" TYPE="REFERENCE">Pignon 2000</LINK>). </P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) was to assess the impact of adding chemotherapy to radiotherapy on overall survival. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Trials were eligible if accrual had been completed before 31st December 2001. Each trial had to be randomised in a manner precluding prior knowledge of treatment assignment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Previously untreated patients with non-metastatic nasopharyngeal carcinoma (WHO type 1, 2 or 3).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials were eligible if radiotherapy plus chemotherapy had been compared to radiotherapy alone as a potentially curative loco-regional treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The main endpoint was overall survival which was evaluated from the time of randomisation until death, whatever the cause. The survival of living patients was taken into account in the analyses until the date of their last follow up. The secondary endpoint was event-free survival (EFS), i.e. the time from randomisation until the first event including loco-regional/distant failure or death.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Published and unpublished trials performed between 1975 and 2001 were included. Computerised searches of MEDLINE and EMBASE were supplemented with handsearches of meeting abstracts and references in review articles. Trial registers managed by the National Cancer Institute (PDQ®, ClinProt) were consulted. Experts, pharmaceutical companies and all trialists who took part in the meta-analysis were asked to identify trials. This first search ended in May 2001. A second-line search was done by Dr Thephamongkhol in October 2003: The literature was searched using MEDLINE (1966 through October 2003), EMBASE (1980 through October 2003), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 3, 2003), the Physician Data Query (PDQ®) database, the Canadian Medical Association (CMA) Infobase, the National Guideline Clearinghouse, and abstracts published in the proceedings of the meetings of the American Society of Clinical Oncology (1997 to 2003), the American Society for Therapeutic Radiology and Oncology (1992 to 2002), the Asian Clinical Oncology Society (2001), the International Congress of Radiation Oncology (1997 and 2001), the European Society of Therapeutic Radiology and Oncology (1992, 1994, 1996, 1998, 2000 and 2002), and the European Society for Medical Oncology (2000 and 2002). Article bibliographies and personal files were also searched to October 2003 for evidence relevant to this practice guideline report. The literature search combined nasopharyngeal disease specific terms (nasopharyngeal neoplasms/ or nasopharyn:.mp. or nasopharyngeal.tw.) with treatment specific terms (drug therapy/ or chemotherapy/ or chemotherapy.tw. or radiochemotherapy.mp. or chemoradiotherapy.mp.) and search specific terms for the following study designs: practice guidelines, systematic reviews, meta-analyses, reviews, randomised controlled trials and clinical trials (<LINK REF="REF-Thephamongkhol-2004" TYPE="REFERENCE">Thephamongkhol 2004</LINK>). A second-line search of Chinese and occidental literature was carried out by Dr Thephamongkhol in October 2003.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The meta-analysis was based on individual patient data (<LINK REF="REF-Pignon-2001" TYPE="REFERENCE">Pignon 2001</LINK>) and used a methodology similar to that used in the MACH-NC study (<LINK REF="REF-Pignon-2000" TYPE="REFERENCE">Pignon 2000</LINK>) and the Prophylactic Cranial Irradiation Overview (<LINK REF="REF-Auperin-1999" TYPE="REFERENCE">Auperin 1999</LINK>). </P>
<P>All data were checked for internal consistency and compared with the trial protocol and published reports. Ranges were checked and extremes were verified with the trialists. Each trial was re-analysed and the analyses were sent to the trialists for review.</P>
<P>The data collected for each patient included: age, gender, WHO performance status (or equivalent), histology (WHO), TNM (Tumour, Node, Metastasis) staging, treatment allocated, date of randomisation, cause of death, date of loco-regional failure, date of distant failure, date and type of second primary, exclusion (yes/no) from the trial analysis and the reason for exclusion, at least one cycle of chemotherapy received (yes/no). As different TNM staging classifications were used in the publications, authors who used the Ho classification in their publication were requested to provide, if possible, American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) staging. The last follow-up and survival status were updated as far as possible, as compared with the published analyses. Early deaths (i.e. within three months) were also studied. </P>
<P>All analyses were on an intention-to-treat basis that is, all randomised patients were included in the analyses according to the allocated treatment, irrespective of whether they received the treatment or whether they were excluded from the investigator's original analysis. Median follow up was quantified using the potential follow-up method (<LINK REF="REF-Schemper-1996" TYPE="REFERENCE">Schemper 1996</LINK>). Survival analyses were stratified by trial, and the log rank Observed minus Expected number of deaths (O-E) and its variance were used to calculate individual and overall pooled hazard ratios with a fixed-effect model (<LINK REF="REF-EBCTCG-1990" TYPE="REFERENCE">EBCTCG 1990</LINK>). The absolute differences in the two and five year survival rates were calculated using the pooled hazard ratio and the assumption of proportional hazards was used to calculate survival rates at two and five years using the control radiotherapy group (<LINK REF="REF-Stewart-1993" TYPE="REFERENCE">Stewart 1993</LINK>). Non-stratified Kaplan-Meier survival curves are presented for the control and the treatment groups. Chi-square heterogeneity tests were used to test for statistical heterogeneity among trials (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). The percentage of variability in the estimates of the treatment effect due to heterogeneity between studies rather than sampling errors was estimated by I² statistics (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). A limited number of comparisons, planned in the meta-analysis protocol, were done between subsets of trials and subgroups of patients, and a test for interaction or a test for trend was performed to look for any significant variation in the treatment effect among these subgroups/subsets (<LINK REF="REF-NSCLCCG-1995" TYPE="REFERENCE">NSCLCCG 1995</LINK>). All P-values are two-sided. </P>
<P>The meta-analysis protocol (<LINK REF="REF-MAC_x002d_NPC-2004" TYPE="REFERENCE">MAC-NPC 2004</LINK>) specified that covariates to be considered would be: Age in three categories as in the MACH-NC study, but as the patient population was younger in this study, another distribution was used corresponding to the tertiles (40 or less, 41 to 50, 51+), gender, performance status (WHO, 0, 1, 2+), TNM stage and histologic type. Tumour stage was divided into three categories according to the 1997 AJCC/UICC classification (T1, T2, T3 to 4) because five trials used AJCC/UICC classifications before 1997, one trial used Ho's classification, and the other two used the 1997 AJCC/UICC classification, thus rendering the distinction between T3 and T4 patients impossible. Node stages had to be divided into three categories (N0, N1 to 2, N3) for the same reason. We could not use the data from the trial that used Ho's classification (<LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>) for this covariate because nodes are classified topographically in Ho's staging system. Histologic types were divided into two categories (WHO 1 versus 2 to 3): we had to pool patients with WHO type 2 and 3 carcinoma because data were missing in one trial (only patients with WHO type 2 and 3 carcinoma were included). Trials were grouped according to the timing of chemotherapy: induction (before radiotherapy), concomitant (chemotherapy given concomitantly with radiotherapy) and adjuvant (after radiotherapy). Trials combining induction and adjuvant chemotherapy or concomitant and adjuvant chemotherapy were respectively included in the induction group and in the concomitant group. Trials were also grouped according to the type of chemotherapy: cisplatin + 5-FU-based chemotherapy versus other chemotherapy. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-05 16:13:01 +0000" MODIFIED_BY="Jenny Bellorini">
<STUDY_DESCRIPTION MODIFIED="2008-11-05 16:12:17 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Eleven trials including 2722 patients were identified in the English language literature. The data from one trial were lost at the institution (<LINK REF="STD-Rossi-1988" TYPE="STUDY">Rossi 1988</LINK>) (229 patients). We received data from ten trials. Two trials were excluded by the Steering Committee after blind review (740 patients) because they did not fulfil the eligibility criterion of unpredictable treatment assignment (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>; <LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>).</P>
<P>Eighty-eight comparative trials were found in the Chinese literature (<LINK REF="REF-Thephamongkhol-2004" TYPE="REFERENCE">Thephamongkhol 2004</LINK>) (list available on request). Twelve were selected according to criteria based on a quality score (<LINK REF="REF-Thephamongkhol-2004" TYPE="REFERENCE">Thephamongkhol 2004</LINK>), on size and on the duration of the follow up (1775 patients). We managed to contact nine teams. Data from three trials were lost. Five teams failed to respond despite numerous attempts. Only one database was obtained (<LINK REF="STD-Pan-2000" TYPE="STUDY">Pan 2000</LINK>) (300 patients) but the trial was also excluded by the Steering Committee after blind review for the same reason as the other two trials.</P>
<P>The database thus included the eight trials (<LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK>; <LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>; <LINK REF="STD-Chan-2002" TYPE="STUDY">Chan 2002</LINK>; <LINK REF="STD-Chi-2002" TYPE="STUDY">Chi 2002</LINK>; <LINK REF="STD-Chua-1998" TYPE="STUDY">Chua 1998</LINK>; <LINK REF="STD-Cvitkovic-1996" TYPE="STUDY">Cvitkovic 1996</LINK>; <LINK REF="STD-Hareyama-2002" TYPE="STUDY">Hareyama 2002</LINK>; <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>; ), described in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. All of them have been published as a full paper.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All the studies fulfilled our quality criteria. Inclusion curves were compared between both arms to look for randomisation abnomalities. Very few data were missing. Only two trials (299 patients) had a median follow up of less than five years.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-05 16:13:01 +0000" MODIFIED_BY="Jenny Bellorini">
<SUBSECTION>
<HEADING LEVEL="3">Population</HEADING>
<P>The eight trials included 1753 patients. Overall, 728 deaths (42%) were observed. The median follow up was six years (range 3 to 9). On the intention-to-treat basis, 63 randomised patients who had been excluded from the published studies were included in the present analysis (4%).</P>
<P>One trial had a 2 x 2 design. The 222 patients in this trial were therefore counted twice resulting in a total number of 11 comparisons based on 1975 patients (<LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>; <LINK REF="STD-Kwong-2004b" TYPE="STUDY">Kwong 2004b</LINK>; <LINK REF="STD-Kwong-2004c" TYPE="STUDY">Kwong 2004c</LINK>; <LINK REF="STD-Kwong-2004d" TYPE="STUDY">Kwong 2004d</LINK>). All trials used conventional radiotherapy, and some patients in one trial (<LINK REF="STD-Cvitkovic-1996" TYPE="STUDY">Cvitkovic 1996</LINK>) received hypofractionated radiotherapy. The doses delivered to the primary tumour site ranged between 65 and 74 Gray (Gy) delivered in 6.5 to 8 weeks. Patients with N0 disease received 50 to 66 Gy. Patients with positive nodes received between 60 and 76 Gy. The 76 Gy dose resulted from an additional boost delivered in case of residual nodes after completion of the treatment in some of the patients in two trials (<LINK REF="STD-Chua-1998" TYPE="STUDY">Chua 1998</LINK>; <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>). Four comparisons (<LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>; <LINK REF="STD-Chua-1998" TYPE="STUDY">Chua 1998</LINK>; <LINK REF="STD-Cvitkovic-1996" TYPE="STUDY">Cvitkovic 1996</LINK>; <LINK REF="STD-Hareyama-2002" TYPE="STUDY">Hareyama 2002</LINK>) (830 patients) investigated induction chemotherapy. In one of them (<LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>) (77 patients), adjuvant chemotherapy was added to induction chemotherapy. Four comparisons (<LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK>; <LINK REF="STD-Chan-2002" TYPE="STUDY">Chan 2002</LINK>; <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>; <LINK REF="STD-Kwong-2004d" TYPE="STUDY">Kwong 2004d</LINK>) (765 patients) investigated concomitant chemotherapy. In one of them (<LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK>) (193 patients), adjuvant chemotherapy was added to concomitant chemotherapy. Three comparisons (<LINK REF="STD-Chi-2002" TYPE="STUDY">Chi 2002</LINK>; <LINK REF="STD-Kwong-2004b" TYPE="STUDY">Kwong 2004b</LINK>; <LINK REF="STD-Kwong-2004c" TYPE="STUDY">Kwong 2004c</LINK>) (380 patients) investigated adjuvant chemotherapy alone (including a comparison of concomitant chemotherapy versus concomitant chemotherapy + adjuvant chemotherapy). Three comparisons investigated monochemotherapy: UFT (uracil + tegafur) in 222 patients (<LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>), cisplatin in 350 patients (<LINK REF="STD-Chan-2002" TYPE="STUDY">Chan 2002</LINK>). The eight other comparisons investigated cisplatin-based polychemotherapy: cisplatin + 5-fluorouracil (5-FU) +/- other drugs in 730 patients (<LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK>; <LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>; <LINK REF="STD-Chi-2002" TYPE="STUDY">Chi 2002</LINK>; <LINK REF="STD-Hareyama-2002" TYPE="STUDY">Hareyama 2002</LINK>; <LINK REF="STD-Kwong-2004b" TYPE="STUDY">Kwong 2004b</LINK>) and cisplatin + epirubicin +/- bleomycin in 673 patients (<LINK REF="STD-Chua-1998" TYPE="STUDY">Chua 1998</LINK>; <LINK REF="STD-Cvitkovic-1996" TYPE="STUDY">Cvitkovic 1996</LINK>).</P>
<P>Ninety-three percent of the patients in the radiotherapy + chemotherapy group received at least one cycle of chemotherapy versus 0.1% in the radiotherapy alone group. Patient characteristics are described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of chemotherapy on overall survival </HEADING>
<P>There was a significant 18% reduction in the hazard ratio (HR) of death (P = 0.006) with chemotherapy (HR = 0.82, 95% confidence interval (CI) 0.71 to 0.95). This reduction corresponds to an absolute survival benefit of 4% at two years, from 77% to 81%, and of 6% at five years, from 56% to 62%. There was significant heterogeneity between trials (P = 0.03; I² = 50%) largely due to the timing of chemotherapy (P = 0.005). The concomitant trials showed a better treatment effect than induction trials or adjuvant trials (HR = 0.60, 95%CI 0.48 to 0.76) versus HR = 0.99 (CI 0.80 to 1.21) and HR = 0.97 (CI 0.69 to 1.38)). The proportion of early deaths, i.e. within the three months after randomisation, was 1.6%, in the radio-chemotherapy group and 1.2% in the radiotherapy alone group. The only excess treatment-related deaths were observed in the radio-chemotherapy group in induction chemotherapy trials. The survival curves can be found in <LINK REF="REF-Baujat-2006" TYPE="REFERENCE">Baujat 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of chemotherapy on event-free survival</HEADING>
<P>The number of events observed was 1044. There was a significant 24% reduction in the hazard ratio of tumour failure or death (P &lt; 0.00001) for event-free survival with chemotherapy (HR = 0.76, 95% CI 0.67 to 0.86). This reduction corresponds to an absolute event-free survival benefit of 9% at two years, from 54% to 63%, and of 10% at five years, from 42% to 52%. There was no significant heterogeneity between trials (P = 0.14; I<SUP>2 </SUP>= 32.5%) and no significant interaction between timings of chemotherapy (P = 0.09). HR = 0.82 (95% CI 0.68 to 0.97) in the induction trials, HR = 0.63 (95% CI 0.51 to 0.78) in the concomitant trials, and HR = 0.90 (95% CI 0.67 to 1.20) in the adjuvant trials.</P>
<P>Events were loco-regional failure (46%), distant failure (38%), both loco-regional and distant failure (5%), and death without failure (11%). Data on the type of failure were missing for one trial (<LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK>). Chemotherapy lowered the risk of loco-regional failure (P = 0.003, HR = 0.76, 95% CI 0.63 to 0.91) as well as that of the distant failure (P = 0.001, HR = 0.72, 95% CI 0.59 to 0.88). There was no significant interaction between the timing of chemotherapy and loco-regional control (P = 0.89), nor between the timing of chemotherapy and distant control (P = 0.19). The event-free survival curves can be found in <LINK REF="REF-Baujat-2006" TYPE="REFERENCE">Baujat 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interactions between treatment effect and trial characteristics</HEADING>
<P>A significant beneficial effect of chemotherapy was observed on both event-free survival and overall survival in the subset of six trials (730 patients; two induction, one concomitant plus adjuvant and three adjuvant trials) using cisplatin + 5-FU: HR of tumour failure or death was 0.69 (95% CI 0.56 to 0.85) and HR of death, 0.74 (95% CI 0.59 to 0.93). A significant benefit was observed for event-free survival, but not for overall survival in the other subset of five trials (1245 patients; two induction and three concomitant trials): HR of tumour failure or death, 0.80 (95% CI 0.69 to 0.93) and HR of death, 0.87 (95% CI 0.73 to 1.04). However, the difference between these treatment effects was not significant either for event-free survival (P = 0.25) or for overall survival (P = 0.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interactions between treatment effect and patient characteristics</HEADING>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> summarises the statistical analyses exploring the interactions between patient characteristics and the treatment effect. There was no significant interaction between the treatment effect and age, gender performance status, T stage or N stage. No significant interaction was found between T stage or N stage and the treatment effect within each subset of trials grouped according to the timing of chemotherapy. The only significant interaction was between the WHO histologic type and the effect of chemotherapy: chemotherapy was more efficient against WHO type 1 disease than against WHO type 2, 3 disease (P = 0.003 for overall survival and P &lt; 0.0001 for event-free survival).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses </HEADING>
<P>Sensitivity analyses were performed to check the robustness of the results (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). After exclusion of patients with WHO type 1 disease, the overall result remained significantly in favour of chemotherapy (P = 0.03), and this exclusion diminished the heterogeneity between trials, which was no longer significant (P = 0.09). As 49 out of 55 patients with WHO type 1 disease were from the <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> trial, analyses were also performed after exclusion of this trial. The overall benefit of chemotherapy remained significant for event-free survival (P = 0.002), but not for overall survival (P = 0.17). However, the treatment effect remained significant for the concomitant subset even though the hazard ratio increased from 0.60 (95% CI 0.48 to 0.76) to 0.71 (95% CI 0.53 to 0.94). Excluding a small trial, two trials with less than five years of follow up, and the two comparisons using a control group that received chemotherapy did not significantly modify overall results (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Despite numerous trials investigating the effect of chemotherapy on nasopharyngeal carcinoma, to date there is no consensus about the magnitude of its benefit and the optimal protocol. An individual patient data meta-analysis was therefore justified. The exhaustiveness principle of meta-analysis was impossible to reach because of the difficulties encountered when trying to include Chinese trials. This is why the term "pooled analysis" could also be applied to the present study. The quality of the missing data remains unknown, while the quality of our data has been thoroughly checked. Very few data are missing from the trials included which comply with long-term follow up. Data on 11 trials and 2793 patients were collected. The quality of the trials, especially concerning randomisation, was verified. Three trials totalling 1040 patients were excluded because they did not fulfil the eligibility criterion of unpredictable treatment assignment (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>; <LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>; <LINK REF="STD-Pan-2000" TYPE="STUDY">Pan 2000</LINK>). Our meta-analysis demonstrates a small but significant treatment effect in terms of overall survival and event-free survival. These results seem to be robust, as confirmed by our sensitivity analyses. It is noteworthy that chemotherapy also seems to be active in terms of loco-regional control (HR = 0.76) and distant control (HR = 0.72). </P>
<P>A second meta-analysis based on published results was reported recently (<LINK REF="REF-Langedijk-2004" TYPE="REFERENCE">Langedijk 2004</LINK>). Its results included two of the three trials that we excluded (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>; <LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>), but it did not include the results of the <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK> trial nor the overall survival data from the <LINK REF="STD-Chan-2002" TYPE="STUDY">Chan 2002</LINK> trial. The individual patient data from an old trial (<LINK REF="STD-Rossi-1988" TYPE="STUDY">Rossi 1988</LINK>) included in their meta-analysis were lost and therefore were not included in our results. Literature-based meta-analyses tend to have limitations: no quality control of data, analyses are not based on the intention-to-treat principle in all the trials, analyses of the interaction between prognostic factors and treatment effects are not possible, and trials are not necessarily updated. These differences may explain why the effect of chemotherapy observed in our meta-analysis in the concomitant group of trials is smaller than the effect observed in their meta-analysis. However, in that study, the observed effect of chemotherapy on overall survival is close to our findings.</P>
<P>The treatment effect could be dependent on the timing of chemotherapy: no evidence of an overall survival benefit was observed with induction and adjuvant chemotherapy, unlike that evidenced with concomitant chemotherapy. A benefit for event-free survival was however demonstrated in the subset of trials with induction chemotherapy. In this group, there was an excess of treatment-related deaths in the chemo-radiotherapy group. This may suggest that if toxicity was better managed, which is the case in the more recent trials, induction chemotherapy may play a role. The observed effect in the subset of trials with adjuvant chemotherapy could be attributable to the absence of an effect on distant control. However, the power of our study may be insufficient to demonstrate this hypothesis. The <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> trial, in which adjuvant chemotherapy was added to concomitant chemotherapy, was included in the concomitant chemotherapy group. However, the impact of adjuvant chemotherapy in this trial remains unclear, as there was poor compliance with adjuvant chemotherapy which was also the case in the <LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK> trial (adjuvant after induction chemotherapy): only 55% patients in these trials completed the adjuvant chemotherapy protocol. In addition, when adjuvant chemotherapy was used alone, the trials failed to demonstrate a positive impact either in terms of overall survival or event-free survival. In the present meta-analysis, the <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> trial was the only trial to demonstrate a significant overall survival benefit imputable to chemotherapy. Some controversy arose about the relevance of this trial because 49 of the 193 patients had WHO type 1 carcinoma, and survival in the control group was lower than usual (<LINK REF="REF-Chua-2000" TYPE="REFERENCE">Chua 2000</LINK>). Furthermore, trial accrual was stopped early due to the highly significant survival benefit evidenced at the time of the first planned interim analysis. Stopping the trial early may have artificially led to an overestimation of the treatment effect. Two trials should clarify this point: the SQNP01 trial conducted by the Nasopharynx Cancer work group in Singapore (Wee 2005a) confirms the results of the <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> trial: a significant benefit in favour of chemotherapy is observed (HR = 0.51; 95% CI 0.31 to 0.81; P = 0.006). The compliance with adjuvant chemotherapy is also low in this trial: only 57% of the patients completed the adjuvant chemotherapy protocol. The preliminary results of the trial conducted by the Hong Kong Nasopharyngeal Cancer Study group and the Princess Margaret Hospital in Canada (Lee 2005a) do not demonstrate any effect of this protocol on overall survival. A longer follow up is needed for this trial. However, the result of our meta-analysis cannot simply be attributable to the <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> trial, because the event-free survival benefit for the whole group of trials and the overall survival benefit in the concomitant group afforded by chemotherapy remained significant after exclusion of this trial. In our meta-analysis, only 55 patients had WHO type 1 carcinoma, and they account for part of the heterogeneity of the treatment effects. This heterogeneity may have stemmed from a significantly more pronounced treatment effect of chemotherapy in this subgroup of patients. As most of these patients were from the <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> trial where a strong treatment effect was observed, a bias may have been introduced, but this is probably not the case, because the treatment effect in this trial was also more pronounced among patients with WHO type 1 carcinoma. However, the difference in the treatment effect between patients with WHO type 1 carcinoma and those with WHO type 2 and 3 carcinoma was not significantly different. No other significant interaction between the effect of chemotherapy and patient characteristics could be found.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The adjunction of chemotherapy to standard radiotherapy provides a small but significant survival benefit in patients with nasopharyngeal carcinoma. This benefit is essentially observed when chemotherapy is administered concomitantly with radiotherapy. The role of induction chemotherapy and adjuvant chemotherapy given alone or added to concomitant or induction chemotherapy is more questionable. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Due to the heterogeneity of the chemotherapy protocols, this meta-analysis does not allow conclusions on the superiority of a chemotherapy regimen. Furthermore, the different timings used to deliver different drugs can interfere with the results. Induction chemotherapy trials showed a benefit in event-free survival and the lack of effect on overall survival may find an explanation in the excess of toxic deaths. Following the positive results of taxane-based induction chemotherapy protocols in head and neck squamous cell carcinoma, it may be useful to design trials investigating induction chemotherapy plus concomitant chemotherapy versus concomitant chemotherapy alone in nasopharyngeal cancer.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-03-24 09:51:40 +0000" MODIFIED_BY="[Empty name]">
<P>We are grateful to Denise Avenell for secretariat support, Francine Courtial for trial search, Catherine Hill for her comments on the manuscript and Lorna Saint Ange for editing.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-03-24 09:51:45 +0000" MODIFIED_BY="[Empty name]">
<P>Aventis had a general agreement with Institut Gustave Roussy to support meta-analyses on lung and head and neck cancers. Sanofi supported part of the investigator meeting. Schering-Plough (a company not directly interested in the project) provided a travelling expenses grant for the first author to attend the ASTRO meeting to present the MAC-NPC project. The grant was awarded after the acceptance of the abstract. The study sponsors played no role in the study design, data collection, data analysis, data interpretation or writing of the report.</P>
<P>The authors declare that they have no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>B Baujat supervised the data analysis and wrote the paper. H Audry did the data collection and the statistical analysis. J Bourhis and JP Pignon had the original idea, designed the study and revised the paper. JP Pignon also supervised data collection and statistical analyses. The investigators provided the data, answered queries sent to secretariat and validated the re-analysis of trials. The other authors reviewed and commented on the preliminary results and the manuscript. The members of the Steering Committee also reviewed the protocol and the data from trials with eligibility problems. K Thephamongkhol contributed to data collection and revised the paper.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2009-05-13 12:32:41 +0100" MODIFIED_BY="Jenny Bellorini">
<SUBSECTION>
<HEADING LEVEL="2">May 2009: updating of this review</HEADING>
<P>This is a review of individual patient data.  Whilst standard Cochrane Reviews are updated every two years, we believe that the updating of this review is premature because:</P>
<UL>
<LI>induction chemotherapy is a major issue since the onset of TPF (taxane, platinum, 5FU) protocols. We know of two ongoing trials which are testing TPF for nasopharyngeal carcinoma and think it would be pertinent to defer the update of this review until they publish at least their preliminary results;</LI>
<LI>two newly published trials confirm the results of the previously published trials and no different conclusions would be drawn from their inclusion. This systematic review was not underpowered, as concomitant chemotherapy was shown to provide a significant benefit in terms of survival.</LI>
</UL>
</SUBSECTION>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-07-27 16:27:03 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDIES MODIFIED="2009-07-27 16:27:03 +0100" MODIFIED_BY="Jenny Bellorini">
<INCLUDED_STUDIES MODIFIED="2009-07-27 16:27:03 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="MIX" ID="STD-Al_x002d_Sarraf-1998" NAME="Al-Sarraf 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;INT-0099&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Al-Sarraf M, LeBlanc M, Shanker PG, Fu KK, Cooper J, Vuong T, et al</AU>
<TI>Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1310-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chan-1995" NAME="Chan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;PWH-88&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chan ATC, Teo PML, Leung TW, Leung SF, Lee WY, Yeo W, et al</AU>
<TI>A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>33</VL>
<PG>569-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chan-2002" NAME="Chan 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;PWHQEH-94&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chan ATC, Teo PML, Ngan RK, Leung TW, Lau WH, Zee B, et al</AU>
<TI>Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma : Progression-free survival analysis of a phase III randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>2038-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chi-2002" NAME="Chi 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;TCOG-94&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chi KH, Chang Y, Guo W, Shiau C, Wang L, Hsu M, et al</AU>
<TI>A phase III study of adjuvant chemotherapy in advanced stage nasopharyngeal carcinoma patients</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chua-1998" MODIFIED="2009-07-27 16:27:03 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Chua 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-27 16:27:00 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al</AU>
<TI>Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>5</NO>
<PG>1300-6. Epub 2006 Jun 5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;AOCOA&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, et al</AU>
<TI>Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma</TI>
<SO>Cancer</SO>
<YR>1998</YR>
<VL>83</VL>
<PG>2270-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cvitkovic-1996" NAME="Cvitkovic 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;VUMCA-89&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cvitkovic E, Eschwege F, Rahal M, Dosen D, Mersic Z, Krajina Z et al</AU>
<TI>Preliminary results of trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV ( N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression free survival</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>35</VL>
<PG>463-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hareyama-2002" NAME="Hareyama 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Japan-91&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, et al</AU>
<TI>A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in advanced nasopharyngeal carcinoma</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<PG>2217-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kwong-2004a" NAME="Kwong 2004a" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;2X2 design. Comparison radiotherapy + concomitant chemotherapy versus radiotherapy alone&lt;br&gt;QMH-95 conc&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kwong DLW, Sham JST, Au GKH, Chua DTT, Kwong PWK, Cheng ACK et al</AU>
<TI>Concurrent and adjuvant Chemotherapy for Nasopharyngeal carcinoma: a factorial study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2643-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kwong-2004b" NAME="Kwong 2004b" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;2X2 design. Comparison radiotherapy + adjuvant chemotherapy versus radiotherapy alone&lt;br&gt;QMH-95adj&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kwong DLW, Sham JST, Au GKH, Chua DTT, Kwong PWK, Cheng ACK et al</AU>
<TI>Concurrent and adjuvant Chemotherapy for Nasopharyngeal carcinoma: a factorial study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2643-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kwong-2004c" NAME="Kwong 2004c" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;2X2 design. Comparison radiotherapy + concomitant +adjuvant chemotherapy versus radiotherapy + concomitant chemotherapy&lt;br&gt;QMH-95adj+&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kwong DLW, Sham JST, Au GKH, Chua DTT, Kwong PWK, Cheng ACK et al</AU>
<TI>Concurrent and adjuvant Chemotherapy for Nasopharyngeal carcinoma: a factorial study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2643-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kwong-2004d" NAME="Kwong 2004d" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;2X2 design. Comparison radiotherapy + concomitant + adjuvant chemotherapy versus radiotherapy + adjuvant chemotherapy&lt;br&gt;QMH-95conc+&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kwong DLW, Sham JST, Au GKH, Chua DTT, Kwong PWK, Cheng ACK et al</AU>
<TI>Concurrent and adjuvant Chemotherapy for Nasopharyngeal carcinoma: a factorial study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2643-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Lin-2003" NAME="Lin 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY</AU>
<TI>Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>631-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ma-2001" NAME="Ma 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al</AU>
<TI>Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>1350-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pan-2000" NAME="Pan 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pan J, Lin S, Wu J</AU>
<TI>Long-term results of a prospective randomized study on nasopharyngeal carcinoma treated by radiotherapy combined with induction or concurrent chemotherapy</TI>
<SO>Chinese Journal of Radiation Oncology</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>221-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi-1988" NAME="Rossi 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, et al</AU>
<TI>Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in loco-regional nasopharyngeal cancer: results of 4-years multicenter randomized study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>1401-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-05-13 12:15:22 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2008" MODIFIED="2009-05-13 12:13:39 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Chen 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-05-13 12:13:33 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, et al</AU>
<TI>Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2008</YR>
<VL>71</VL>
<NO>5</NO>
<PG>1356-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hui-2009" MODIFIED="2009-05-13 12:15:22 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Hui 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-05-13 12:15:19 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al</AU>
<TI>Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>2</NO>
<PG>242-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lee-2005" MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Lee 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AW, Lau WH, Tung SY, Chua D, Chappell R, Xu L, Siu L et al</AU>
<TI>Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced Nasopharyngeal Carcinoma: NPC-9901 trial by the Hong-Kong Nasopharyngeal Cancer Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>6966-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wee-2005" MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Wee 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wee J, Tan EH, Tia BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee K M, Fong KW et al</AU>
<TI>Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>6730-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lee-2006" NAME="Lee 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, et al</AU>
<TI>Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>66</VL>
<PG>142-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VUMCA-II" NAME="VUMCA II" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zhang-2005" MODIFIED="2009-05-13 11:51:52 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Zhang 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Zhang L, Zhao C, Peng PJ, Lu LX, Han F, Wu SX. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005;23:8461-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Zhao C, Peng PJ, Lu LX, Han F, Wu SX</AU>
<TI>Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>8461-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-05 16:19:19 +0000" MODIFIED_BY="Jenny Bellorini">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-05 16:19:19 +0000" MODIFIED_BY="Jenny Bellorini">
<REFERENCE ID="REF-Ali-2000" NAME="Ali 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ali H, Al-Sarraf M</AU>
<TI>Chemotherapy in advanced nasopharyngeal cancer</TI>
<SO>Oncology (Huntingt)</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>1223-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Auperin-1999" NAME="Auperin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Auperin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PEG, Johnson B, Ueoka H, Wagner H, Aisner J</AU>
<TI>Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission : a meta-analysis of individual data from 987 patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>476-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baujat-2006" NAME="Baujat 2006" NOTES="&lt;p&gt;Baujat B, H&amp;#233;l&amp;#232;ne Audry H, Jean Bourhis J, Chan ATC, Onat H, Chua DTT, Kwong DLW, Al-Sarraf M, Chi K-H, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP, on behalf of the MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma. An individual patient data meta-analysis of 8 randomised trials and 1&amp;#160;753 patients. Int J Rad Oncol Biol Phys 2006;64:47-56.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Baujat B, Hélène Audry H, Jean Bourhis J, Chan ATC, Onat H, Chua DTT, Kwong DLW, Al-Sarraf M, Chi K-H, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP, on behalf of the MAC-NPC Collaborative Group</AU>
<TI>Chemotherapy in locally advanced nasopharyngeal carcinoma. An individual patient data meta-analysis of 8 randomised trials and 1753 patients</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>64</VL>
<PG>47-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chua-2000" NAME="Chua 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chua DTT, Sham JST / Wong JR, Wang CC / Siu LL, Tannock IF / Vikram B</AU>
<TI>The Ali / Alsarraf article reviewed</TI>
<SO>Oncology (Huntingt)</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>1232-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EBCTCG-1990" NAME="EBCTCG 1990" TYPE="BOOK">
<AU>Early Breast Cancer Trialist's Collaborative Group</AU>
<SO>Treatment of early breast cancer. Worldwide evidence 1985-1990</SO>
<YR>1990</YR>
<VL>1</VL>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langedijk-2004" NAME="Langedijk 2004" TYPE="JOURNAL_ARTICLE">
<AU>Langedijk JA, Leemans R, Buter J, Berkhof J, Slotman BJ</AU>
<TI>The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>4604-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MAC_x002d_NPC-2004" MODIFIED="2008-11-05 16:19:19 +0000" MODIFIED_BY="Jenny Bellorini" NAME="MAC-NPC 2004" TYPE="COCHRANE_PROTOCOL">
<AU>MAC-NPC (Meta-Analysis of Chemotherapy in Naso-Pharynx Carcinoma) Group</AU>
<TI>Chemotherapy for nasopharyngeal carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 16:19:19 +0000" MODIFIED_BY="Jenny Bellorini">
<IDENTIFIER MODIFIED="2008-11-05 16:19:19 +0000" MODIFIED_BY="Jenny Bellorini" TYPE="DOI" VALUE="Art. No.: CD004329. DOI: 10.1002/14651858.CD004329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NSCLCCG-1995" NAME="NSCLCCG 1995" TYPE="JOURNAL_ARTICLE">
<AU>The Non-Small Cell Lung Cancer Collaborative Group</AU>
<TI>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated individual patient data from 52 randomised clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pignon-2000" NAME="Pignon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pignon JP, Bourhis J, Domenge C, Désigné L on behalf of the MACH-NC Collaborative Group</AU>
<TI>Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analysis of updated individual data</TI>
<SO>The Lancet</SO>
<YR>2000</YR>
<VL>255</VL>
<PG>949-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pignon-2001" NAME="Pignon 2001" TYPE="JOURNAL_ARTICLE">
<AU>Pignon JP, Hill C</AU>
<TI>Meta-analysis of randomised clinical trials in oncology</TI>
<SO>The Lancet Oncology</SO>
<YR>2001</YR>
<VL>2</VL>
<PG>475-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schemper-1996" NAME="Schemper 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schemper M, Smith TL</AU>
<TI>A note on quantifying follow-up in studies of failure time</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1993" NAME="Stewart 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stewart LA, Parmar MKB</AU>
<TI>Meta-analysis of the literature or of individual data: is there a difference?</TI>
<SO>The Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>418-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thephamongkhol-2004" NAME="Thephamongkhol 2004" TYPE="JOURNAL_ARTICLE">
<AU>Thephamongkhol K, Zhou J, Browman G, Wong RKW, Chan JCK, Zeng Y, Thabane L, Hodson I, Oliver T</AU>
<TI>Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22 (Supplement: abstract proceeding)</VL>
<PG>5522</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vokes-1997" NAME="Vokes 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vokes EE, Liebowitz DN, Weichselbaum RR</AU>
<TI>Nasopharyngeal carcinoma</TI>
<SO>The Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>1087-91</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-27 16:23:48 +0100" MODIFIED_BY="Jenny Bellorini">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-05 16:14:20 +0000" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Al_x002d_Sarraf-1998">
<CHAR_METHODS>
<P>Inclusion period: 1989 to 1995. <BR/>Median follow up: 110 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>193 patients. Stages III to IV (AJCC &lt; 1997). Histology WHO 1 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor: 70 Gray/7 weeks. N- 50 Gray, N+ 66 to 70 Gray<BR/>+/- concomitant Cisplatin: 100 mg/m² x 3 and adjuvant Cisplatin: 80 mg/m² x 3 cycles and Fluorouracil: 4000 mg/m² x 3 cycles, continuous infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>24% of type 1 histology, concomitant cisplatin every 3 weeks, adjuvant cisplatin + 5-fluorouracil every 4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chan-1995">
<CHAR_METHODS>
<P>Inclusion period: 1988 to 1991. <BR/>Median follow up: 35 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>77 patients. Stage III to IV (Ho classification). Histology WHO 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor: 66 Gray/6.5 weeks. N- 58 Gray, N+ 65.5 Gray<BR/>+/- induction and adjuvant chemotherapy: Cisplatin: 100 mg/m² x (induction 2 cycles and adjuvant 4 cycles) and Fluorouracil: 3000 mg/m² x (induction 2 cycles and adjuvant 4 cycles), continuous infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 cycles of induction and 4 cycles of adjuvant chemotherapy. Radiotherapy : nasopharynx, equivalent of 66 Gy with conventional fractionation + 20 Gy boost if parapharyngeal disease + 18 to 24 Gy using 192Ir if residual disease 4 weeks after radiotherapy; neck: 58 Gy for lower neck, 66 Gy for upper neck.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chan-2002">
<CHAR_METHODS>
<P>Inclusion period: 1994 to 1999. <BR/>Median follow up: 67 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>350 patients. Stages II to IV (AJCC 1997). Histology WHO 1 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor: 66 Gray/6.5 weeks. N- 58 Gray, N+ 65.5 Gray<BR/>+/- concomitant Cisplatin: 40 mg/m² , weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>10 or 20 Gy (depending on the centre) boost if parapharyngeal disease, 21 to 24 Gy using 192Ir if residual local disease after radiotherapy, 7.5 Gy boost if residual nodal disease, radical neck dissection if proven residual neck nodes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chi-2002">
<CHAR_METHODS>
<P>Inclusion period: 1994 to 1999. <BR/>Median follow up: 72 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>158 patients. Stage IV (AJCC &lt; 1997). Histology WHO 1 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor: 70 to 72 Gray/7 to 8 weeks. N- 50 Gray lower neck<BR/>+/- Adjuvant Cisplatin: 20 mg/m² x 9 weekly, Fluorouracil: 2200 mg/m² x 9 weekly, Leucovorin acid: 120 mg/m² x 9 weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All drugs provided by continuous injections.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chua-1998">
<CHAR_METHODS>
<P>Inclusion period: 1989 to 1993. <BR/>Median follow up: 65 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>334 patients. Stages II to IV (AJCC &lt; 1997). Histology WHO 2 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor 66 to 74 Gray/6.5 to 7.5 weeks. N- 60 to 66 Gray, N+ 66 to 76 Gray.<BR/>+/- Induction chemotherapy: Cisplatin: 60 mg/m² x 2 to 3; Epirubicin: 110 mg/m² x 2 to 3.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cvitkovic-1996">
<CHAR_METHODS>
<P>Inclusion period: 1989 to 1993. <BR/>Median follow up: 84 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>339 patients. Stages III to IV (AJCC &lt; 1997). Histology WHO 1 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor 65 to 70 Gray/6.5 to 7.5 weeks. N- 50 Gray, N+ 65 Gray.<BR/>+/- Induction chemotherapy: Bleomycin: 15 mg/m² x 3; Bleomycin: 60 mg/m² x 3, continuous injection; Epirubicin: 70 mg/m² x 3; Cisplatin: 100 mg/m² x 3.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>110 patients treated with conventional radiotherapy and 176 patients with hypofractionated radiotherapy, 2.5 Gy x 3/weeks followed by 3.5 Gy x 3/week.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hareyama-2002">
<CHAR_METHODS>
<P>Inclusion period: 1991 to 1998. <BR/>Median follow up: 74 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>80 patients. Stages I to IV (AJCC &lt; 1997). Histology WHO 1 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor: 66 to 68 Gray/6.5 to 7 weeks. N- 50 Gray, N+ 66 to 68 Gray<BR/>+/- induction chemotherapy: Cisplatin: 80 mg/m² x 2 cycles and Fluorouracil: 3200 mg/m² x 2 cycles, continuous infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kwong-2004a">
<CHAR_METHODS>
<P>Inclusion period: 1995 to 2000. <BR/>Median follow up: 57 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>222 patients. Stages II to IV (AJCC 1997). Histology WHO 1 to 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy: Tumor: 62.5 to 68 Gray/7 weeks. N 62.5 to 66 Gray/7weeks +/- boost 10 Gray<BR/>+/- concomitant UFT 600 mg daily po / Adjuvant Cisplatin: 100 mg/m² x 3, Fluorouracil: 3000 mg/m² x 3, Vincristine: 2mg x 3, Bleomycin: 30 mg x 3, Methotrexate: 150 mg/m² x 3<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, Event-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 X 2 design, concomitant chemotherapy versus none, adjuvant chemotherapy versus none, concomitant+adjuvant chemotherapy versus adjuvant chemotherapy, concomitant +adjuvant chemotherapy versus concomitant chemotherapy ; for adjuvant chemotherapy, alternating cycles of cisplatin + 5-fluorouracil and vincristine + bleomycin + methotrexate. +/- 10 Gy additional boost in case of parapharyngeal space involvement and/or palpable residual nodes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-05 16:13:50 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kwong-2004b">
<CHAR_METHODS MODIFIED="2008-11-05 16:13:50 +0000" MODIFIED_BY="Jenny Bellorini">
<P>See <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-05 16:13:55 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kwong-2004c">
<CHAR_METHODS MODIFIED="2008-11-05 16:13:55 +0000" MODIFIED_BY="Jenny Bellorini">
<P>See <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-05 16:14:00 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kwong-2004d">
<CHAR_METHODS MODIFIED="2008-11-05 16:14:00 +0000" MODIFIED_BY="Jenny Bellorini">
<P>See <LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<LINK REF="STD-Kwong-2004a" TYPE="STUDY">Kwong 2004a</LINK> (QMH-95 conc), <LINK REF="STD-Kwong-2004b" TYPE="STUDY">Kwong 2004b</LINK> (QMH-95adj), <LINK REF="STD-Kwong-2004c" TYPE="STUDY">Kwong 2004c</LINK> (QMH-95adj+), <LINK REF="STD-Kwong-2004d" TYPE="STUDY">Kwong 2004d</LINK> (QMH-95conc+): 4 comparisons issued from QMH-95 2x2 trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Lin-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not properly randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ma-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not properly randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pan-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not properly randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossi-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Individual data lost by the institution.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-07-27 16:23:48 +0100" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-07-27 16:20:34 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Chen-2008">
<CHAR_METHODS MODIFIED="2009-07-27 16:18:52 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomized phase III trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-27 16:20:34 +0100" MODIFIED_BY="Jenny Bellorini">
<P>316 (158 per group) locoregionally advanced nasopharyngeal carcinomas</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 16:20:32 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Radiotherapy (70 Grays in 7 weeks) plus concurrent cisplatin (40 mg/m² weekly) followed by adjuvant cisplatin (80 mg/m² on day 1) + 5 Fluoro-Uracil (800 mg/m² on days 1 to 5) every 4 weeks for 3 cycles versus same radiotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 16:20:29 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Significant benefit in favour of chemotherapy arm on:<BR/>2-year overall survival rate (89.8% versus 79.7%, P = 0.003)<BR/>2-year failure-free survival rate (84.6% versus 72.5%, P = 0.001)<BR/>2-year distant failure-free survival rate (86.5% versus 78.7% P = 0.024)<BR/>2-year locoregional failure-free survival rate (98% versus 91.9%, P = 0.007)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-27 16:20:17 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Notes: more toxicity and lower compliance in the chemotherapy arm</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-07-27 16:23:48 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hui-2009">
<CHAR_METHODS MODIFIED="2009-07-27 16:22:18 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomized phase II trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-27 16:22:33 +0100" MODIFIED_BY="Jenny Bellorini">
<P>65 (34 CT + CRT versus 31 CRT) stage III to IVb nasopharyngeal carcinomas</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 16:22:43 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Induction docetaxel (75 mg/m²) + cisplatin (75 mg/m²) every 3 weeks for 2 cycles followed by radiotherapy (conventional or IMRT) + concurrent cisplatin (40 mg/m²) weekly versus same radiotherapy + same concurrent cisplatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-27 16:23:42 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Significant benefit on overall survival in favour of induction chemotherapy arm: <BR/>3-year overall survival: 94.1% versus 67.7%, Hazard Ratio = 0.24 (95% CI 0.078 to 0.73), P = 0.012<BR/>3-year progression-free survival 88.2% versus 59.5%, Hazard Ratio = 0.49 (95% CI 0.20 to 1.19), P = 0.12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-27 16:23:48 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Notes: induction CT followed by concurrent RT + CT was well tolerated</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Lee-2005">
<CHAR_METHODS MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini"/>
<CHAR_PARTICIPANTS MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini">
<P>335</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini">
<P>RT versus RT + Concomitant Cisplatin + Adjuvant Cisplatin + 5FU versus RT + Induction CT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini">
<P>No significant benefit on overall survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-13 12:05:55 +0100" MODIFIED_BY="Jenny Bellorini">
<P>See footnotes</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Wee-2005">
<CHAR_METHODS MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini"/>
<CHAR_PARTICIPANTS MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<P>221</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<P>RT versus RT + Concomitant Cisplatin + Adjuvant Cisplatin + 5FU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Significant benefit from CT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini">
<P>See footnotes</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-05-13 12:07:21 +0100" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Lee-2006">
<CHAR_STUDY_NAME>
<P>NPC99-02</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>189</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RT versus accelerated RT versus RT + Concomitant Cisplatin + Adjuvant Cisplatin + 5FU versus accelerated RT + Concomitant Cisplatin + Adjuvant Cisplatin + 5FU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Preliminary results in favour of accelerated RT + chemotherapy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Lee AW, Hong Kong Nasopharyngeal Cancer Study Group and the Princess Margaret Hospital in Canada</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>See footnotes</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-VUMCA-II">
<CHAR_STUDY_NAME>
<P>VUMCA II</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>509</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Induction CT+ RT versus Induction CT + RT + concomitant CT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not ready for analysis</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>1996</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Institut Gustave-Roussy<BR/>Dr E. Benhamou</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Zhang-2005">
<CHAR_STUDY_NAME>
<P>Sun Yat-Sen University</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>77</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RT versus RT + concomitant oxaliplatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Significant benefit from CT</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Cancer Centre of Sun Yat Sen University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>See footnotes</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Recently published as a full paper:<BR/>- Lee AW, Lau W H, Tung S Y, Chua D, Chappell R, Xu L, Siu L et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced Nasopharyngeal Carcinoma: NPC-9901 trial by the Hong-Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23: 6966-75. <BR/>- Wee J, Tan EH, Tia BC, Wong H B, Leong S S, Tan T, Chua E T, Yang E, Lee K M,.Fong KW et al. Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-38.<BR/>- Zhang L, Zhao C, Peng PJ, Lu LX, Han F, Wu SX. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005; 23: 8461-68.<BR/>- Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, Chua DT, O'Sullivan B, Xu SL, Pang ES, Sze WM, Leung TW, Kwan WH, Chan PT, Liu XF, Tan EH, Sham JS, Siu L, Lau WH. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006 ;66:142-51.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Al_x002d_Sarraf-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chan-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chan-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chi-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chua-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cvitkovic-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hareyama-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kwong-2004a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kwong-2004b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kwong-2004c">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kwong-2004d">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-05 16:16:42 +0000" MODIFIED_BY="Jenny Bellorini">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-05 16:15:33 +0000" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE>Patient characteristics by treatment group</TITLE>
<TABLE COLS="3" ROWS="19">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Characteristics</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>RT + CT</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>RT</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n = 1975</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n = 990</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n = 985</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gender: male</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>74%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Age: &lt; 40 or equal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41 to 50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51+</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Perform. status (n = 1468)*: 0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Tumour stage: T1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T3,4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nodal stage (n = 1 898)**: N0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N1,2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Histology (n = 1636)***: WHO 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>WHO 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>WHO 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="3" VALIGN="TOP">
<P>* Data missing from three trials.<BR/>** Data missing from one trial, using Ho's classification.<BR/>*** Data missing from one trial, that did not distinguish between WHO histologic type 2 and 3 but did not include type 1.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-11-05 16:15:52 +0000" MODIFIED_BY="Jenny Bellorini" NO="2">
<TITLE>Treatment effect on overall and event-free survival according to patient charact</TITLE>
<TABLE COLS="6" ROWS="18">
<TR>
<TH VALIGN="BOTTOM">
<P>Characteristics</P>
</TH>
<TH VALIGN="BOTTOM">
<P>n. patients RT+CT/RT</P>
</TH>
<TH VALIGN="BOTTOM">
<P>HR of death (95%CI)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>P-value</P>
</TH>
<TH VALIGN="BOTTOM">
<P>HR tum. failur/death</P>
</TH>
<TH VALIGN="BOTTOM">
<P>P-value</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gender: Male</P>
</TD>
<TD VALIGN="TOP">
<P>742/727</P>
</TD>
<TD VALIGN="TOP">
<P>0.81 (0.69 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.76 (0.66 to 0.87)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gender: Female</P>
</TD>
<TD VALIGN="TOP">
<P>248/258</P>
</TD>
<TD VALIGN="TOP">
<P>0.85 (0.62 to 1.16)</P>
</TD>
<TD VALIGN="TOP">
<P>0.81</P>
</TD>
<TD VALIGN="TOP">
<P>0.74 (0.58 to 0.96)</P>
</TD>
<TD VALIGN="TOP">
<P>0.89</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Age &lt; 40 or equal</P>
</TD>
<TD VALIGN="TOP">
<P>326/285</P>
</TD>
<TD VALIGN="TOP">
<P>0.85 (0.63 to 1.14)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.67 (0.52 to 0.85)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>41 to 50</P>
</TD>
<TD VALIGN="TOP">
<P>308/327</P>
</TD>
<TD VALIGN="TOP">
<P>0.77 (0.59 to 1.01)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.80 (0.64 to 1.00)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 50</P>
</TD>
<TD VALIGN="TOP">
<P>356/373</P>
</TD>
<TD VALIGN="TOP">
<P>0.86 (0.70 to 1.05)</P>
</TD>
<TD VALIGN="TOP">
<P>0.85 (t for trend)</P>
</TD>
<TD VALIGN="TOP">
<P>0.79 (0.66 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>0.31 (t for trend)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Performance status: 0</P>
</TD>
<TD VALIGN="TOP">
<P>380/368</P>
</TD>
<TD VALIGN="TOP">
<P>0.89 (0.71 to 1.11)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.64 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>342/340</P>
</TD>
<TD VALIGN="TOP">
<P>0.71 (0.55 to 0.92)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.66 (0.53 to 0.83)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>17/21</P>
</TD>
<TD VALIGN="TOP">
<P>1.55 (0.65 to 3.69)</P>
</TD>
<TD VALIGN="TOP">
<P>0.73 (t for trend)</P>
</TD>
<TD VALIGN="TOP">
<P>1.40 (0.65 to 3.02)</P>
</TD>
<TD VALIGN="TOP">
<P>0.92 (t for trend)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>T stage (AJCC97): T1</P>
</TD>
<TD VALIGN="TOP">
<P>267/272</P>
</TD>
<TD VALIGN="TOP">
<P>0.68 (0.51 to 0.90)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.54 to 0.87)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>T2</P>
</TD>
<TD VALIGN="TOP">
<P>350/363</P>
</TD>
<TD VALIGN="TOP">
<P>0.83 (0.64 to 1.07)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.82 (0.66 to 1.02)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>T3/T4</P>
</TD>
<TD VALIGN="TOP">
<P>373/350</P>
</TD>
<TD VALIGN="TOP">
<P>0.90 (0.73 to 1.12)</P>
</TD>
<TD VALIGN="TOP">
<P>0.12 (t for trend)</P>
</TD>
<TD VALIGN="TOP">
<P>0.73 (0.60 to 0.88)</P>
</TD>
<TD VALIGN="TOP">
<P>0.80 (t for trend)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>N stage (AJCC97): N0</P>
</TD>
<TD VALIGN="TOP">
<P>91/83</P>
</TD>
<TD VALIGN="TOP">
<P>1.02 (0.61 to 1.69)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.65 (0.42 to 1.00)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>N1/N2</P>
</TD>
<TD VALIGN="TOP">
<P>620/643</P>
</TD>
<TD VALIGN="TOP">
<P>0.82 (0.68 to 0.99)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.79 (0.68 to 0.93)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>N3</P>
</TD>
<TD VALIGN="TOP">
<P>242/219</P>
</TD>
<TD VALIGN="TOP">
<P>0.68 (0.52 to 0.88)</P>
</TD>
<TD VALIGN="TOP">
<P>0.24 (t for trend)</P>
</TD>
<TD VALIGN="TOP">
<P>0.64 (0.51 to 0.81)</P>
</TD>
<TD VALIGN="TOP">
<P>0.47 (t for trend)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>WHO type 1</P>
</TD>
<TD VALIGN="TOP">
<P>29/26</P>
</TD>
<TD VALIGN="TOP">
<P>0.30 (0.15 to 0.59)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.18 (0.09 to 0.36)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>WHO type 2 to 3</P>
</TD>
<TD VALIGN="TOP">
<P>958/959</P>
</TD>
<TD VALIGN="TOP">
<P>0.85 (0.73 to 0.98)</P>
</TD>
<TD VALIGN="TOP">
<P>0.003</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.69 to 0.89)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
<TD VALIGN="TOP">
<P>990/985</P>
</TD>
<TD VALIGN="TOP">
<P>0.82 (0.71 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>0.006</P>
</TD>
<TD VALIGN="TOP">
<P>0.76 (0.67 to 0.86)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 0.0001</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-11-05 16:16:42 +0000" MODIFIED_BY="Jenny Bellorini" NO="3">
<TITLE>Sensitivity analyses</TITLE>
<TABLE COLS="10" ROWS="7">
<TR>
<TH VALIGN="BOTTOM">
<P>Trials included</P>
</TH>
<TH VALIGN="BOTTOM">
<P>N patients RT+CT/RT</P>
</TH>
<TH VALIGN="BOTTOM">
<P>OS. HR. 95%CI</P>
</TH>
<TH VALIGN="BOTTOM">
<P>OS. HR. p-value</P>
</TH>
<TH VALIGN="BOTTOM">
<P>OS. heterogeneity I²</P>
</TH>
<TH VALIGN="BOTTOM">
<P>OS. Hetero. p-value</P>
</TH>
<TH VALIGN="BOTTOM">
<P>EFS. HR. 95%CI</P>
</TH>
<TH VALIGN="BOTTOM">
<P>EFS. HR. p-value</P>
</TH>
<TH VALIGN="BOTTOM">
<P>EFS. hetero. I²</P>
</TH>
<TH VALIGN="BOTTOM">
<P>EFS. Hetero. p-value</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All trials</P>
</TD>
<TD VALIGN="TOP">
<P>990/985</P>
</TD>
<TD VALIGN="TOP">
<P>0.82 (0.71 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>0.006</P>
</TD>
<TD VALIGN="TOP">
<P>50%</P>
</TD>
<TD VALIGN="TOP">
<P>0.03</P>
</TD>
<TD VALIGN="TOP">
<P>0.76 (0.67 to 0.86)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 0.0001</P>
</TD>
<TD VALIGN="TOP">
<P>32%</P>
</TD>
<TD VALIGN="TOP">
<P>0.14</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Without <LINK REF="STD-Al_x002d_Sarraf-1998" TYPE="STUDY">Al-Sarraf 1998</LINK> (INT-0099)</P>
</TD>
<TD VALIGN="TOP">
<P>893/889</P>
</TD>
<TD VALIGN="TOP">
<P>0.90 (0.77 to 1.05)</P>
</TD>
<TD VALIGN="TOP">
<P>0.17</P>
</TD>
<TD VALIGN="TOP">
<P>0%</P>
</TD>
<TD VALIGN="TOP">
<P>0.37</P>
</TD>
<TD VALIGN="TOP">
<P>0.82 (0.72 to 0.93)</P>
</TD>
<TD VALIGN="TOP">
<P>0.002</P>
</TD>
<TD VALIGN="TOP">
<P>0%</P>
</TD>
<TD VALIGN="TOP">
<P>0.99</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Without patients with WHO 1 carcinoma</P>
</TD>
<TD VALIGN="TOP">
<P>958/959</P>
</TD>
<TD VALIGN="TOP">
<P>0.85 (0.73 to 0.98)</P>
</TD>
<TD VALIGN="TOP">
<P>0.03</P>
</TD>
<TD VALIGN="TOP">
<P>38%</P>
</TD>
<TD VALIGN="TOP">
<P>0.09</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.69 to 0.89)</P>
</TD>
<TD VALIGN="TOP">
<P>0.0001</P>
</TD>
<TD VALIGN="TOP">
<P>0%</P>
</TD>
<TD VALIGN="TOP">
<P>0.58</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Without one small trial (<LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK> (PWH-88))</P>
</TD>
<TD VALIGN="TOP">
<P>953/945</P>
</TD>
<TD VALIGN="TOP">
<P>0.81 (0.70 to 0.93)</P>
</TD>
<TD VALIGN="TOP">
<P>0.003</P>
</TD>
<TD VALIGN="TOP">
<P>51%</P>
</TD>
<TD VALIGN="TOP">
<P>0.03</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.66 to 0.85)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 0.0001</P>
</TD>
<TD VALIGN="TOP">
<P>36%</P>
</TD>
<TD VALIGN="TOP">
<P>0.12</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Without QMH-95 combined arms<BR/>(<LINK REF="STD-Kwong-2004d" TYPE="STUDY">Kwong 2004d</LINK> (QMH-95conc+), <LINK REF="STD-Kwong-2004c" TYPE="STUDY">Kwong 2004c</LINK> (QMH-95adj+))</P>
</TD>
<TD VALIGN="TOP">
<P>876/875</P>
</TD>
<TD VALIGN="TOP">
<P>0.84 (0.73 to 0.98)</P>
</TD>
<TD VALIGN="TOP">
<P>0.02</P>
</TD>
<TD VALIGN="TOP">
<P>53%</P>
</TD>
<TD VALIGN="TOP">
<P>0.03</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.66 to 0.85)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 0.0001</P>
</TD>
<TD VALIGN="TOP">
<P>43%</P>
</TD>
<TD VALIGN="TOP">
<P>0.08</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Without <LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK> (PWH-88), QMH95: follow up &lt; 5 years</P>
</TD>
<TD VALIGN="TOP">
<P>729/725</P>
</TD>
<TD VALIGN="TOP">
<P>0.80 (0.68 to 0.93)</P>
</TD>
<TD VALIGN="TOP">
<P>0.004</P>
</TD>
<TD VALIGN="TOP">
<P>58%</P>
</TD>
<TD VALIGN="TOP">
<P>0.04</P>
</TD>
<TD VALIGN="TOP">
<P>0.73 (0.64 to 0.84)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 0.0001</P>
</TD>
<TD VALIGN="TOP">
<P>32%</P>
</TD>
<TD VALIGN="TOP">
<P>0.03</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Radiotherapy versus radiotherapy + chemotherapy</NAME>
<IPD_OUTCOME CHI2="19.962479588507115" CI_END="0.9451046118845572" CI_START="0.7126473661372363" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="0.8206864884861238" ESTIMABLE="YES" EVENTS_1="364" EVENTS_2="413" I2="49.90602266785914" I2_Q="81.24523952399367" ID="CMP-001.01" LOG_CI_END="-0.024520117575710963" LOG_CI_START="-0.14712531562464062" LOG_EFFECT_SIZE="-0.0858227166001758" NO="1" P_CHI2="0.029609595658090626" P_Q="0.004834502776759453" P_Z="0.006071031270422651" Q="10.663959172172188" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="990" TOTAL_2="985" WEIGHT="99.99999999999997" Z="2.7439200991234136">
<NAME>Effect of chemotherapy on overall survival, hazard ratio of death by timing of chemotherapy</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.1370783980569232" CI_END="1.213204263114522" CI_START="0.802573629978444" DF="3" EFFECT_SIZE="0.9867551618071957" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="181" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.08393392772159626" LOG_CI_START="-0.09551511390568296" LOG_EFFECT_SIZE="-0.00579059309204337" NO="1" P_CHI2="0.7681316229067255" P_Z="0.899343188584882" STUDIES="4" TAU2="0.0" TOTAL_1="415" TOTAL_2="415" WEIGHT="46.680497925311194" Z="0.1264911064067352">
<NAME>Induction +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="2.7374178956616104" CI_START="0.6155273051408728" EFFECT_SIZE="1.298058342433417" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.43734110209626936" LOG_CI_START="-0.21075267675544232" LOG_EFFECT_SIZE="0.1132942126704135" ORDER="1" O_E="1.8" SE="0.38069349381344053" STUDY_ID="STD-Chan-1995" TOTAL_1="37" TOTAL_2="40" VAR="6.9" WEIGHT="3.5788381742738586"/>
<IPD_DATA CI_END="1.4401921283040509" CI_START="0.6792029160389101" EFFECT_SIZE="0.9890311891949595" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="55" LOG_CI_END="0.15842043285661103" LOG_CI_START="-0.16800045819271223" LOG_EFFECT_SIZE="-0.00479001266805057" ORDER="2" O_E="-0.3" SE="0.1917412472118426" STUDY_ID="STD-Chua-1998" TOTAL_1="167" TOTAL_2="167" VAR="27.2" WEIGHT="14.107883817427384"/>
<IPD_DATA CI_END="1.3264739832357932" CI_START="0.7474487097387466" EFFECT_SIZE="0.9957265022442706" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="93" LOG_CI_END="0.12269873637795073" LOG_CI_START="-0.12641860346063388" LOG_EFFECT_SIZE="-0.0018599335413415645" ORDER="3" O_E="-0.2" SE="0.1463327585719048" STUDY_ID="STD-Cvitkovic-1996" TOTAL_1="171" TOTAL_2="168" VAR="46.7" WEIGHT="24.22199170124481"/>
<IPD_DATA CI_END="1.454179551639632" CI_START="0.3993487752759367" EFFECT_SIZE="0.7620530316051488" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.16261803339510403" LOG_CI_START="-0.39864764312513223" LOG_EFFECT_SIZE="-0.11801480486501406" ORDER="4" O_E="-2.5" SE="0.32969023669789355" STUDY_ID="STD-Hareyama-2002" TOTAL_1="40" TOTAL_2="40" VAR="9.2" WEIGHT="4.771784232365144"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="5.368007427391186" CI_END="0.7616644158480401" CI_START="0.47895236087390425" DF="3" EFFECT_SIZE="0.6039875579546833" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="167" I2="44.11334111253309" ID="CMP-001.01.02" LOG_CI_END="-0.11823633370926862" LOG_CI_START="-0.319707681655355" LOG_EFFECT_SIZE="-0.21897200768231187" NO="2" P_CHI2="0.14674993605096542" P_Z="2.040343303035665E-5" STUDIES="4" TAU2="0.0" TOTAL_1="384" TOTAL_2="381" WEIGHT="37.03319502074688" Z="4.260429614980358">
<NAME>Concomitant +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="0.6757726942612694" CI_START="0.3142018044956768" EFFECT_SIZE="0.4607917099577597" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="66" LOG_CI_END="-0.17019936060971352" LOG_CI_START="-0.502791325087692" LOG_EFFECT_SIZE="-0.33649534284870275" ORDER="1" O_E="-20.3" SE="0.19536616629114087" STUDY_ID="STD-Al_x002d_Sarraf-1998" TOTAL_1="97" TOTAL_2="96" VAR="26.2" WEIGHT="13.58921161825726"/>
<IPD_DATA CI_END="1.0206385571910663" CI_START="0.5163802576023493" EFFECT_SIZE="0.7259735539819705" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="73" LOG_CI_END="0.00887197087355758" LOG_CI_START="-0.28703037015902405" LOG_EFFECT_SIZE="-0.1390791996427332" ORDER="2" O_E="-10.6" SE="0.17381449986274955" STUDY_ID="STD-Chan-2002" TOTAL_1="174" TOTAL_2="176" VAR="33.1" WEIGHT="17.168049792531118"/>
<IPD_DATA CI_END="2.353788821529968" CI_START="0.45573177477883325" EFFECT_SIZE="1.0357105566182236" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.37176749599326325" LOG_CI_START="-0.34129069024566666" LOG_EFFECT_SIZE="0.015238402873798292" ORDER="3" O_E="0.2" SE="0.4188539082916955" STUDY_ID="STD-Kwong-2004a" TOTAL_1="56" TOTAL_2="55" VAR="5.7" WEIGHT="2.9564315352697093"/>
<IPD_DATA CI_END="0.9480185497996932" CI_START="0.20131814921199775" EFFECT_SIZE="0.43686764570555736" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="-0.023183164774981852" LOG_CI_START="-0.6961170708772789" LOG_EFFECT_SIZE="-0.3596501178261303" ORDER="4" O_E="-5.3" SE="0.39528470752104744" STUDY_ID="STD-Kwong-2004d" TOTAL_1="57" TOTAL_2="54" VAR="6.4" WEIGHT="3.3195020746887964"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.79343459088682" CI_END="1.3786546762714735" CI_START="0.6849338654498658" DF="2" EFFECT_SIZE="0.9717444502229758" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="65" I2="28.403550005261856" ID="CMP-001.01.03" LOG_CI_END="0.13945549824936232" LOG_CI_START="-0.16435136026929392" LOG_EFFECT_SIZE="-0.01244793100996583" NO="3" P_CHI2="0.2474080755182314" P_Z="0.8723990917959069" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="189" WEIGHT="16.286307053941908" Z="0.16061188730585615">
<NAME>Adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.3802967826374877" CI_START="0.564227050926876" EFFECT_SIZE="0.8824969025845955" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="0.1399724756795873" LOG_CI_START="-0.2485460961554003" LOG_EFFECT_SIZE="-0.05428681023790645" ORDER="1" O_E="-2.4" SE="0.22821773229381923" STUDY_ID="STD-Chi-2002" TOTAL_1="80" TOTAL_2="78" VAR="19.2" WEIGHT="9.958506224066388"/>
<IPD_DATA CI_END="3.45836783759141" CI_START="0.7860013613682574" EFFECT_SIZE="1.6487212707001282" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.5388711836574698" LOG_CI_START="-0.10457670175421806" LOG_EFFECT_SIZE="0.21714724095162594" ORDER="2" O_E="3.5" SE="0.3779644730092272" STUDY_ID="STD-Kwong-2004b" TOTAL_1="54" TOTAL_2="55" VAR="7.0" WEIGHT="3.630705394190871"/>
<IPD_DATA CI_END="1.6078303805841503" CI_START="0.28819543082823573" EFFECT_SIZE="0.6807123983233854" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.20624023056799573" LOG_CI_START="-0.5403129089551124" LOG_EFFECT_SIZE="-0.16703633919355843" ORDER="3" O_E="-2.0" SE="0.4385290096535146" STUDY_ID="STD-Kwong-2004c" TOTAL_1="57" TOTAL_2="56" VAR="5.2" WEIGHT="2.697095435684647"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="14.823888310865671" CI_END="0.856438024001853" CI_START="0.6708837613262715" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="0.7580041971422076" ESTIMABLE="YES" EVENTS_1="485" EVENTS_2="559" I2="32.541315812058826" I2_Q="59.39506685476363" ID="CMP-001.02" LOG_CI_END="-0.06730405921086087" LOG_CI_START="-0.1733527200510109" LOG_EFFECT_SIZE="-0.12032838963093591" NO="2" P_CHI2="0.1386157924464455" P_Q="0.08519996322463763" P_Z="8.677181549550316E-6" Q="4.925509895180391" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="990" TOTAL_2="985" WEIGHT="100.0" Z="4.447756494536487">
<NAME>Effect of chemotherapy on event-free survival, hazard ratio of tumour failure or death by timing of chemo.</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.1920982096950525" CI_END="0.9719476785149289" CI_START="0.683925131680055" DF="3" EFFECT_SIZE="0.815315548738307" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="263" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.012357113205254356" LOG_CI_START="-0.16499143728256885" LOG_EFFECT_SIZE="-0.08867427524391154" NO="1" P_CHI2="0.7549001652680372" P_Z="0.022767290501575402" STUDIES="4" TAU2="0.0" TOTAL_1="415" TOTAL_2="415" WEIGHT="48.273185875048505" Z="2.2773172008836444">
<NAME>Induction +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.9432212995915177" CI_START="0.5025015353925496" EFFECT_SIZE="0.9881658194110152" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.2885222621122072" LOG_CI_START="-0.2988626069194275" LOG_EFFECT_SIZE="-0.005170172403610159" ORDER="1" O_E="-0.1" SE="0.3450327796711771" STUDY_ID="STD-Chan-1995" TOTAL_1="37" TOTAL_2="40" VAR="8.4" WEIGHT="3.2596041909196742"/>
<IPD_DATA CI_END="1.1581442919007032" CI_START="0.6721319044333568" EFFECT_SIZE="0.8822843807547774" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="108" LOG_CI_END="0.06376267102561821" LOG_CI_START="-0.17254548922874482" LOG_EFFECT_SIZE="-0.05439140910156332" ORDER="2" O_E="-6.5" SE="0.1388085830776715" STUDY_ID="STD-Chua-1998" TOTAL_1="167" TOTAL_2="167" VAR="51.9" WEIGHT="20.139697322467985"/>
<IPD_DATA CI_END="0.9873928102229611" CI_START="0.5774632828425561" EFFECT_SIZE="0.7551046905207834" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="114" LOG_CI_END="-0.005510039453800177" LOG_CI_START="-0.23847562453679075" LOG_EFFECT_SIZE="-0.12199283199529545" ORDER="3" O_E="-15.0" SE="0.13684513787599334" STUDY_ID="STD-Cvitkovic-1996" TOTAL_1="171" TOTAL_2="168" VAR="53.4" WEIGHT="20.721769499417928"/>
<IPD_DATA CI_END="1.276393198235967" CI_START="0.3850744216553954" EFFECT_SIZE="0.7010751547556051" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.10598448121838806" LOG_CI_START="-0.4144553281777072" LOG_EFFECT_SIZE="-0.1542354234796595" ORDER="4" O_E="-3.8" SE="0.30570892025787155" STUDY_ID="STD-Hareyama-2002" TOTAL_1="40" TOTAL_2="40" VAR="10.7" WEIGHT="4.152114862242918"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.303336669341366" CI_END="0.7756592345660795" CI_START="0.5119370966175724" DF="3" EFFECT_SIZE="0.6301497730765022" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="204" I2="63.869946270190624" ID="CMP-001.02.02" LOG_CI_END="-0.11032903267367682" LOG_CI_START="-0.2907833989268546" LOG_EFFECT_SIZE="-0.20055621580026575" NO="2" P_CHI2="0.04014153557519118" P_Z="1.3210361187953428E-5" STUDIES="4" TAU2="0.0" TOTAL_1="384" TOTAL_2="381" WEIGHT="34.53628249902988" Z="4.35659128682614">
<NAME>Concomitant +/-adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="0.5827653214663531" CI_START="0.276341945601061" EFFECT_SIZE="0.4013010126611192" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="71" LOG_CI_END="-0.23450629963351935" LOG_CI_START="-0.5585531890593752" LOG_EFFECT_SIZE="-0.3965297443464473" ORDER="1" O_E="-25.2" SE="0.19034674690672027" STUDY_ID="STD-Al_x002d_Sarraf-1998" TOTAL_1="97" TOTAL_2="96" VAR="27.6" WEIGHT="10.71012805587893"/>
<IPD_DATA CI_END="1.0874168795984982" CI_START="0.5886735579965079" EFFECT_SIZE="0.8000834728568689" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="87" LOG_CI_END="0.036396070121998865" LOG_CI_START="-0.2301254713631553" LOG_EFFECT_SIZE="-0.09686470062057827" ORDER="2" O_E="-9.1" SE="0.15655607277128739" STUDY_ID="STD-Chan-2002" TOTAL_1="174" TOTAL_2="176" VAR="40.8" WEIGHT="15.832363213038416"/>
<IPD_DATA CI_END="1.3235998649754106" CI_START="0.387894508467731" EFFECT_SIZE="0.7165313105737892" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.12175671418407027" LOG_CI_START="-0.4112863687862382" LOG_EFFECT_SIZE="-0.144764827301084" ORDER="3" O_E="-3.4" SE="0.31311214554257477" STUDY_ID="STD-Kwong-2004a" TOTAL_1="56" TOTAL_2="55" VAR="10.2" WEIGHT="3.958090803259604"/>
<IPD_DATA CI_END="1.3242363512924327" CI_START="0.392710685083541" EFFECT_SIZE="0.7211392131402784" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12196550542192361" LOG_CI_START="-0.40592728205097284" LOG_EFFECT_SIZE="-0.14198088831452463" ORDER="4" O_E="-3.4" SE="0.3100868364730211" STUDY_ID="STD-Kwong-2004d" TOTAL_1="57" TOTAL_2="54" VAR="10.4" WEIGHT="4.03570042685293"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.40294353664886173" CI_END="1.201852391003782" CI_START="0.6669214625024346" DF="2" EFFECT_SIZE="0.8952883079323053" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="92" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.07985113180229138" LOG_CI_START="-0.17592530612851873" LOG_EFFECT_SIZE="-0.04803708716311361" NO="3" P_CHI2="0.8175267355607728" P_Z="0.46161064439709587" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="189" WEIGHT="17.190531625921615" Z="0.7361972941962919">
<NAME>Adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.2266656798746538" CI_START="0.547383982526143" EFFECT_SIZE="0.8194248867821423" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="51" LOG_CI_END="0.08872621458551418" LOG_CI_START="-0.261707915004606" LOG_EFFECT_SIZE="-0.0864908502095459" ORDER="1" O_E="-4.7" SE="0.20584674239815456" STUDY_ID="STD-Chi-2002" TOTAL_1="80" TOTAL_2="78" VAR="23.6" WEIGHT="9.157935584012417"/>
<IPD_DATA CI_END="1.7365057270276572" CI_START="0.5465940974181572" EFFECT_SIZE="0.9742503685019284" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.23967621996028976" LOG_CI_START="-0.26233506249437244" LOG_EFFECT_SIZE="-0.011329421267041338" ORDER="2" O_E="-0.3" SE="0.29488391230979427" STUDY_ID="STD-Kwong-2004b" TOTAL_1="54" TOTAL_2="55" VAR="11.5" WEIGHT="4.462553356616221"/>
<IPD_DATA CI_END="1.9290941785406452" CI_START="0.5297704789780032" EFFECT_SIZE="1.010928853559515" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2853534304547187" LOG_CI_START="-0.2759122460655175" LOG_EFFECT_SIZE="0.004720592194600546" ORDER="3" O_E="0.1" SE="0.32969023669789355" STUDY_ID="STD-Kwong-2004c" TOTAL_1="57" TOTAL_2="56" VAR="9.2" WEIGHT="3.570042685292976"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.7665895226283563" CI_END="0.9097458564681816" CI_START="0.6349356957590789" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.7600198144394421" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="260" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.04107991377646437" LOG_CI_START="-0.19727025642633042" LOG_EFFECT_SIZE="-0.11917508510139742" NO="3" P_CHI2="0.9260925504606937" P_Q="0.8896285054061254" P_Z="0.0027810960376759" Q="0.2339026333314953" SCALE="10.0" SORT_BY="USER" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="893" TOTAL_2="889" WEIGHT="100.00000000000001" Z="2.9909515619266127">
<NAME>Effect of chemotherapy on loco-regional control, HR of loco-regional failure by timing of chemotherapy</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.4590891258516416" CI_END="0.9715847985647488" CI_START="0.6007844044091226" DF="3" EFFECT_SIZE="0.7640111219993331" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="144" I2="13.271965802228701" ID="CMP-001.03.01" LOG_CI_END="-0.012519288793927514" LOG_CI_START="-0.22128134958406365" LOG_EFFECT_SIZE="-0.11690031918899564" NO="1" P_CHI2="0.3261071269728769" P_Z="0.028160812082347168" STUDIES="4" TAU2="0.0" TOTAL_1="415" TOTAL_2="415" WEIGHT="55.97643097643098" Z="2.1950388353561774">
<NAME>Induction +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="2.7270641582416233" CI_START="0.19405973266183824" EFFECT_SIZE="0.7274705090242837" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43569535548564786" LOG_CI_START="-0.7120645712422626" LOG_EFFECT_SIZE="-0.13818460787830736" ORDER="1" O_E="-0.7" SE="0.674199862463242" STUDY_ID="STD-Chan-1995" TOTAL_1="37" TOTAL_2="40" VAR="2.2" WEIGHT="1.851851851851852"/>
<IPD_DATA CI_END="1.209058838182945" CI_START="0.6091732098866735" EFFECT_SIZE="0.8582110774149659" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="69" LOG_CI_END="0.08244743607698729" LOG_CI_START="-0.21525920424311928" LOG_EFFECT_SIZE="-0.06640588408306602" ORDER="2" O_E="-5.0" SE="0.17487435419566724" STUDY_ID="STD-Chua-1998" TOTAL_1="167" TOTAL_2="167" VAR="32.7" WEIGHT="27.52525252525253"/>
<IPD_DATA CI_END="0.8749418206132556" CI_START="0.4062100563277043" EFFECT_SIZE="0.5961628688829712" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="61" LOG_CI_END="-0.05802082449388217" LOG_CI_START="-0.39124932919913685" LOG_EFFECT_SIZE="-0.22463507684650952" ORDER="3" O_E="-13.5" SE="0.19574007317156783" STUDY_ID="STD-Cvitkovic-1996" TOTAL_1="171" TOTAL_2="168" VAR="26.1" WEIGHT="21.969696969696972"/>
<IPD_DATA CI_END="2.921493877773985" CI_START="0.5491586964308537" EFFECT_SIZE="1.2666348209129108" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4656049805481309" LOG_CI_START="-0.2603021345575028" LOG_EFFECT_SIZE="0.10265142299531407" ORDER="4" O_E="1.3" SE="0.4264014327112209" STUDY_ID="STD-Hareyama-2002" TOTAL_1="40" TOTAL_2="40" VAR="5.5" WEIGHT="4.62962962962963"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.06705176042862618" CI_END="1.1760744591895667" CI_START="0.5515526466530847" DF="2" EFFECT_SIZE="0.805398647023386" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="57" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.07043481850157657" LOG_CI_START="-0.25841302708656616" LOG_EFFECT_SIZE="-0.09398910429249477" NO="2" P_CHI2="0.9670298843101393" P_Z="0.26255710298743595" STUDIES="3" TAU2="0.0" TOTAL_1="287" TOTAL_2="285" WEIGHT="22.55892255892256" Z="1.120367743465071">
<NAME>Concomitant +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.2963484348021932" CI_START="0.46142289917853313" EFFECT_SIZE="0.7734111798597054" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.11272174765618018" LOG_CI_START="-0.3359008564120179" LOG_EFFECT_SIZE="-0.11158955437791887" ORDER="1" O_E="-3.7" SE="0.26352313834736496" STUDY_ID="STD-Chan-2002" TOTAL_1="174" TOTAL_2="176" VAR="14.4" WEIGHT="12.121212121212123"/>
<IPD_DATA CI_END="1.8067805531427605" CI_START="0.4192347139664593" EFFECT_SIZE="0.8703247258333906" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.25690540748807217" LOG_CI_START="-0.3775427635723088" LOG_EFFECT_SIZE="-0.060318678042118275" ORDER="2" O_E="-1.0" SE="0.37267799624996495" STUDY_ID="STD-Kwong-2004a" TOTAL_1="56" TOTAL_2="55" VAR="7.2" WEIGHT="6.060606060606061"/>
<IPD_DATA CI_END="1.9116420859364807" CI_START="0.34265213619467183" EFFECT_SIZE="0.8093381520636312" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2814065832050969" LOG_CI_START="-0.46514655631801116" LOG_EFFECT_SIZE="-0.09186998655645713" ORDER="3" O_E="-1.1" SE="0.4385290096535146" STUDY_ID="STD-Kwong-2004d" TOTAL_1="57" TOTAL_2="54" VAR="5.2" WEIGHT="4.377104377104377"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.006546003016590599" CI_END="1.039886005323617" CI_START="0.4784754801459998" DF="2" EFFECT_SIZE="0.7053792991677055" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="59" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.016985733556117197" LOG_CI_START="-0.32014031308074004" LOG_EFFECT_SIZE="-0.1515772897623114" NO="3" P_CHI2="0.9967323489269962" P_Z="0.07799116552911287" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="189" WEIGHT="21.464646464646464" Z="1.7624626264984802">
<NAME>Adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.2089473829630633" CI_START="0.4076108506105115" EFFECT_SIZE="0.7019829564262412" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="0.08240739946617551" LOG_CI_START="-0.38975426358232296" LOG_EFFECT_SIZE="-0.1536734320580737" ORDER="1" O_E="-4.6" SE="0.2773500981126146" STUDY_ID="STD-Chi-2002" TOTAL_1="80" TOTAL_2="78" VAR="13.0" WEIGHT="10.942760942760943"/>
<IPD_DATA CI_END="1.5615582489372584" CI_START="0.33559907978475306" EFFECT_SIZE="0.723918166213305" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.19355818883532194" LOG_CI_START="-0.4741792386805001" LOG_EFFECT_SIZE="-0.14031052492258908" ORDER="2" O_E="-2.1" SE="0.3922322702763681" STUDY_ID="STD-Kwong-2004b" TOTAL_1="54" TOTAL_2="55" VAR="6.5" WEIGHT="5.4713804713804715"/>
<IPD_DATA CI_END="1.5426246430386852" CI_START="0.3113559110164912" EFFECT_SIZE="0.6930406200864415" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1882602648264746" LOG_CI_START="-0.5067428848888593" LOG_EFFECT_SIZE="-0.15924131003119235" ORDER="3" O_E="-2.2" SE="0.408248290463863" STUDY_ID="STD-Kwong-2004c" TOTAL_1="57" TOTAL_2="56" VAR="6.0" WEIGHT="5.050505050505051"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="14.675069568264782" CI_END="0.8748993809472927" CI_START="0.5888293217246815" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.7177509380422558" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="220" I2="38.671500273751796" I2_Q="39.912740331598265" ID="CMP-001.04" LOG_CI_END="-0.058041890762899846" LOG_CI_START="-0.2300105717239509" LOG_EFFECT_SIZE="-0.14402623124342537" NO="4" P_CHI2="0.10025685109294469" P_Q="0.18933350774754798" P_Z="0.0010271020692842834" Q="3.328492613970455" SCALE="10.0" SORT_BY="USER" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="893" TOTAL_2="889" WEIGHT="100.0" Z="3.282995769794685">
<NAME>Effect of chemotherapy on distant control, hazard ratio of distant failure by timing of chemotherapy</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="6.10075002636313" CI_END="0.8560663712297788" CI_START="0.49148488455879696" DF="3" EFFECT_SIZE="0.6486475789198138" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="117" I2="50.82571836190435" ID="CMP-001.04.01" LOG_CI_END="-0.06749256296136724" LOG_CI_START="-0.3084898341973597" LOG_EFFECT_SIZE="-0.18799119857936344" NO="1" P_CHI2="0.10681015372261993" P_Z="0.002229976606016869" STUDIES="4" TAU2="0.0" TOTAL_1="415" TOTAL_2="415" WEIGHT="50.91836734693877" Z="3.057760585722695">
<NAME>Induction +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="2.934457331389998" CI_START="0.508381799143292" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.46752779901687896" LOG_CI_START="-0.2938100062555782" LOG_EFFECT_SIZE="0.08685889638065038" ORDER="1" O_E="1.0" SE="0.4472135954999579" STUDY_ID="STD-Chan-1995" TOTAL_1="37" TOTAL_2="40" VAR="5.0" WEIGHT="5.1020408163265305"/>
<IPD_DATA CI_END="1.3034399294188044" CI_START="0.5328101004705866" EFFECT_SIZE="0.8333582421450019" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="41" LOG_CI_END="0.11509102098721351" LOG_CI_START="-0.27342755084777415" LOG_EFFECT_SIZE="-0.07916826493028029" ORDER="2" O_E="-3.5" SE="0.22821773229381923" STUDY_ID="STD-Chua-1998" TOTAL_1="167" TOTAL_2="167" VAR="19.2" WEIGHT="19.591836734693878"/>
<IPD_DATA CI_END="0.7610597832712128" CI_START="0.3299629787423186" EFFECT_SIZE="0.5011202980214958" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="56" LOG_CI_END="-0.11858122690220196" LOG_CI_START="-0.48153478445501874" LOG_EFFECT_SIZE="-0.30005800567861035" ORDER="3" O_E="-15.2" SE="0.21320071635561044" STUDY_ID="STD-Cvitkovic-1996" TOTAL_1="171" TOTAL_2="168" VAR="22.0" WEIGHT="22.448979591836736"/>
<IPD_DATA CI_END="0.9654921597249279" CI_START="0.12580894774056037" EFFECT_SIZE="0.3485219543540323" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.015251248556803466" LOG_CI_START="-0.9002884700500516" LOG_EFFECT_SIZE="-0.45776985930342756" ORDER="4" O_E="-3.9" SE="0.5198752449100363" STUDY_ID="STD-Hareyama-2002" TOTAL_1="40" TOTAL_2="40" VAR="3.7" WEIGHT="3.775510204081633"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.8259146074474486" CI_END="0.9683896592449759" CI_START="0.49145041088704666" DF="2" EFFECT_SIZE="0.6898662884463267" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="76" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.013949856732187618" LOG_CI_START="-0.3085202974953766" LOG_EFFECT_SIZE="-0.16123507711378215" NO="2" P_CHI2="0.4013356445632841" P_Z="0.03190502725414059" STUDIES="3" TAU2="0.0" TOTAL_1="287" TOTAL_2="285" WEIGHT="34.08163265306122" Z="2.1455984746385464">
<NAME>Concomitant +/- adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.1341881738985373" CI_START="0.5234478309769722" EFFECT_SIZE="0.7705117387469982" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="56" LOG_CI_END="0.054685114615132424" LOG_CI_START="-0.28112659545184737" LOG_EFFECT_SIZE="-0.11322074041835747" ORDER="1" O_E="-6.7" SE="0.1972574607881179" STUDY_ID="STD-Chan-2002" TOTAL_1="174" TOTAL_2="176" VAR="25.7" WEIGHT="26.224489795918366"/>
<IPD_DATA CI_END="1.1260568554497299" CI_START="0.10363603619845889" EFFECT_SIZE="0.3416139180901607" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.051560318920935225" LOG_CI_START="-0.984489205972365" LOG_EFFECT_SIZE="-0.46646444352571487" ORDER="2" O_E="-2.9" SE="0.6085806194501846" STUDY_ID="STD-Kwong-2004a" TOTAL_1="56" TOTAL_2="55" VAR="2.7" WEIGHT="2.7551020408163267"/>
<IPD_DATA CI_END="1.3723471753841936" CI_START="0.2377530995622127" EFFECT_SIZE="0.571209063848815" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.13746399277040758" LOG_CI_START="-0.6238738125020495" LOG_EFFECT_SIZE="-0.24320490986582094" ORDER="3" O_E="-2.8" SE="0.4472135954999579" STUDY_ID="STD-Kwong-2004d" TOTAL_1="57" TOTAL_2="54" VAR="5.0" WEIGHT="5.1020408163265305"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.419912320483749" CI_END="1.8464024848336489" CI_START="0.6642096041289083" DF="2" EFFECT_SIZE="1.1074286719757578" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" I2="41.51896854136019" ID="CMP-001.04.03" LOG_CI_END="0.26632637593665126" LOG_CI_START="-0.1776948490176203" LOG_EFFECT_SIZE="0.044315763459515496" NO="3" P_CHI2="0.18087399318725583" P_Z="0.6956269417568639" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="189" WEIGHT="15.000000000000002" Z="0.3912303982179757">
<NAME>Adjuvant chemotherapy</NAME>
<IPD_DATA CI_END="1.4468202003761743" CI_START="0.32882640035849275" EFFECT_SIZE="0.6897482718033083" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.16041456371320756" LOG_CI_START="-0.48303332169848034" LOG_EFFECT_SIZE="-0.16130937899263645" ORDER="1" O_E="-2.6" SE="0.3779644730092272" STUDY_ID="STD-Chi-2002" TOTAL_1="80" TOTAL_2="78" VAR="7.0" WEIGHT="7.142857142857143"/>
<IPD_DATA CI_END="3.443617578847779" CI_START="0.596591567909028" EFFECT_SIZE="1.4333294145603404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5370149161213992" LOG_CI_START="-0.2243228891510579" LOG_EFFECT_SIZE="0.1563460134851707" ORDER="2" O_E="1.8" SE="0.4472135954999579" STUDY_ID="STD-Kwong-2004b" TOTAL_1="54" TOTAL_2="55" VAR="5.0" WEIGHT="5.1020408163265305"/>
<IPD_DATA CI_END="7.726437948508835" CI_START="0.7110985551408998" EFFECT_SIZE="2.343983545499083" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.8879793211049757" LOG_CI_START="-0.14807020378832456" LOG_EFFECT_SIZE="0.3699545586583256" ORDER="3" O_E="2.3" SE="0.6085806194501846" STUDY_ID="STD-Kwong-2004c" TOTAL_1="57" TOTAL_2="56" VAR="2.7" WEIGHT="2.7551020408163267"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2015-04-27 11:16:18 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-04-27 11:16:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-03-24 09:53:57 +0000" MODIFIED_BY="[Empty name]">Feedback received</TITLE>
<DATE_SUBMITTED>
<DATE DAY="16" MONTH="2" YEAR="2015"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-03-24 09:59:18 +0000" MODIFIED_BY="[Empty name]">
<P>This review contains a trial with multiple treatment arms (Kwong, 2004). It appears that the groups of patients from Kwong (2004) have been included more than in the same meta-analysis, leading to unit of analysis issues (see Cochrane handbook section 9.3.9).</P>
<P>I agree with the conflict of interest statement below:</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-04-27 11:16:18 +0100" MODIFIED_BY="[Empty name]">
<P>MAC-NPC was an individual patient-based meta-analysis, meaning that the authors of the meta-analysis obtained the patients' data from all trials included and performed intention-to treat analyses, after a rigorous verification process.</P>
<P>The Kwong trial is a 2 x 2 design trial, thus allowing four comparisons: 'RT versus RT + concomitant CT'; 'RT versus RT + adjuvant CT'; 'RT + concomitant CT versus RT + concomitant CT + adjuvant CT'; and 'RT + adjuvant CT versus RT + adjuvant + concomitant CT'. The 222 patients in this trial, out of the 1753 patients in the meta-analysis were thus counted twice (+13%). This is commonly performed in other meta-analyses (see e.g. MACH-NC, MARCH). Exclusion of the two following comparisons, 'RT + concomitant CT versus RT + concomitant CT + adjuvant CT' and 'RT+ adjuvant CT versus RT + adjuvant + concomitant CT', did not modify its conclusions. This meta-analysis has been updated and will be published very soon in <I>Lancet Oncology</I>.</P>
<P>Bertrand Baujat, 25 March 2015.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-04-27 11:13:37 +0100" MODIFIED_BY="[Empty name]">
<P>Comment from: Nathan Bromham, Researcher, National Collaborating Centre for Cancer, <A HREF="mailto:nathan.bromham@wales.nhs.uk">nathan.bromham@wales.nhs.uk</A>.</P>
<P>Reply from: Dr Bertrand Baujat, Service ORL-CCF, Hôpital Tenon, Paris, France.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>